Freeform Search

Database: US Pre-Grant Publication Full-Text Database
US Patents Full-Text Database
US OCR Full-Text Database
EPO Abstracts Database
JPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Term:

Display: 10 **Documents in Display Format:** REV **Starting with Number** 1

Generate: ○ **Hit List** ◉ **Hit Count** ○ **Side by Side** ○ **Image**

Search Clear Interrupt

Search History

DATE: Wednesday, July 18, 2007 **Purge Queries** Printable Copy Create Case

Set Name side by side	Query	Hit Count	Set Name result set
DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; THES=ASSIGNEE; PLUR=YES; OP=AND			
L13	L12@ay>1998	35	L13
L12	L11 and l10	35	L12
L11	antiobod$ or serum or immunoglobulin or monoclonal or polyclonal	284836	L11
L10	SdrG	46	L10
L9	L1 and SdrG	0	L9
L8	L2 and SdrG	5	L8
L7	L3 and SdrG	25	L7
L6	L5 and SdrG	5	L6
L5	hartford.in.	296	L5
L4	nieidhin.in.	2	L4
L3	hook.in.	1893	L3
L2	mccrea.in.	361	L2
L1	foster-t.in.	38	L1

END OF SEARCH HISTORY

Refine Search

Search Results -

Term	Documents
(15 NOT 16).PGPB,USPT,USOC,EPAB,JPAB,DWPI.	39
(L15 NOT L16).PGPB,USPT,USOC,EPAB,JPAB,DWPI.	39

Database:
US Pre-Grant Publication Full-Text Database
US Patents Full-Text Database
US OCR Full-Text Database
EPO Abstracts Database
JPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Search: L17

Refine Search

Recall Text Clear Interrupt

Search History

DATE: Wednesday, July 18, 2007 **Purge Queries** Printable Copy Create Case

Set Name side by side	Query	Hit Count	Set Name result set
DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; THES=ASSIGNEE; PLUR=YES; OP=AND			
L17	l15 not L16	39	L17
L16	L15@ay>1998	74	L16
L15	L14 and l11	113	L15
L14	l10 or Fbe	6066	L14
L13	L12@ay>1998	35	L13
L12	L11 and l10	35	L12
L11	antiobod$ or serum or immunoglobulin or monoclonal or polyclonal	284836	L11
L10	SdrG	46	L10
L9	L1 and SdrG	0	L9
L8	L2 and SdrG	5	L8
L7	L3 and SdrG	25	L7
L6	L5 and SdrG	5	L6

L5	hartford.in.	296	L5
L4	nieidhin.in.	2	L4
L3	hook.in.	1893	L3
L2	mccrea.in.	361	L2
L1	foster-t.in.	38	L1

END OF SEARCH HISTORY

```
?  e au=foster, timothy
Ref   Items  Index-term
E1       12  AU=FOSTER, TIM J.
E2        1  AU=FOSTER, TIMONTHY J.
E3       17  AU=FOSTER, TIMOTHY
E4        1  AU=FOSTER, TIMOTHY A
E5        1  AU=FOSTER, TIMOTHY D.
E6        1  AU=FOSTER, TIMOTHY DAVID
E7        1  AU=FOSTER, TIMOTHY E
E8       49  AU=FOSTER, TIMOTHY J
E9      124  AU=FOSTER, TIMOTHY J.
E10       2  AU=FOSTER, TIMOTHY JAMES
E11      10  AU=FOSTER, TIMOTHY JOHN
E12      14  AU=FOSTER, TIMOTHY P
E13      17  AU=FOSTER, TIMOTHY P.
E14       2  AU=FOSTER, TIMOTHY PAUL
E15       1  AU=FOSTER, TIMOTHY R.V.
E16       1  AU=FOSTER, TIMOTHY. J.
E17       1  AU=FOSTER, TINA C.
E18      89  AU=FOSTER, TJ
E19      11  AU=FOSTER, TJ*
E20       2  AU=FOSTER, TL
E21      27  AU=FOSTER, TM
E22       2  AU=FOSTER, TM*
E23       1  AU=FOSTER, TOBIAS
E24       1  AU=FOSTER, TODD
E25       1  AU=FOSTER, TODD J.
          Enter PAGE for more

?  s e1-e3, e8-e11
Processing
Processing
Processing
           12   AU=FOSTER, TIM J.
            1   AU=FOSTER, TIMONTHY J.
           17   AU=FOSTER, TIMOTHY
           49   AU=FOSTER, TIMOTHY J
          124   AU=FOSTER, TIMOTHY J.
            2   AU=FOSTER, TIMOTHY JAMES
           10   AU=FOSTER, TIMOTHY JOHN
S1        215   S E1-E3, E8-E11

?  s antiobod$ or serum or immunoglobulin or monoclonal or polyclonal
Processing
Processing
Processing
Processing
Processing
Processing
Processing
Processing
Processing
Processing
Processing
Processing
Processing
Processing
Processing
Processing
Processing
Processing
Processing
```

```
Processing
Processing
Processing
Processing
Processing
Processing
Processing
Processing
Processing
Processing
Processing
Processing
Processing
Processing
Processing
Processing
Processing
Processing
Processing
Processing
Processing
Processing
Processing
Processing
Processing
Processing
Processing
Processing
Processing
              0   ANTIOBOD$
        3846004   SERUM
        1022729   IMMUNOGLOBULIN
        1319626   MONOCLONAL
         256894   POLYCLONAL
S2      5844286   S ANTIOBOD$ OR SERUM OR IMMUNOGLOBULIN OR MONOCLONAL OR POLYCLONAL

?
?  s antiobod? or serum or immunoglobulin or monoclonal or polyclonal
Processing
Processing
Processing
Processing
Processing
Processing
Processing
Processing
Processing
Processing
Processing
Processing
Processing
Processing
Processing
Processing
Processing
Processing
Processing
Processing
Processing
Processing
Processing
Processing
Processing
```

```
Processing
Processing
Processing
Processing
Processing
Processing
Processing
Processing
Processing
Processing
Processing
Processing
Processing
Processing
Processing
Processing
Processing
Processing
Processing
Processing
Processing
          86   ANTIOBOD?
     3846004   SERUM
     1022729   IMMUNOGLOBULIN
     1319626   MONOCLONAL
      256894   POLYCLONAL
S3   5844319   S ANTIOBOD? OR SERUM OR IMMUNOGLOBULIN OR MONOCLONAL OR POLYCLONAL

?  s SdrG or Sdr or Fbe
Processing
Processing
Processing
Processing
         134   SDRG
        7772   SDR
        1055   FBE
S4      8909   S SDRG OR SDR OR FBE

?
?
?  s s3 and s4
Processing
Processing
Processing
Processing
Processing
Processing
Processing
Processing
Processing
Processing
Processing
Processing
Processing
Processing
Processing
Processing
Processing
Processing
Processing
Processing
Processing
Processing
Processing
Processing
Processing
Processing
Processing
Processing
Processing
Processing
Processing
```

```
Processing
Processing
Processing
Processing
Processing
Processing
Processing
Processing
Processing
Processing
Processing
Processing
Processing
Processing
Processing
Processing
Processing
Processing
Processing
Processing
Processing
      5844319   S3
         8909   S4
S5        395   S S3 AND S4

?  s s5 and fibrinogen
Processing
Processing
Processing
Processing
Processing
Processing
Processing
Processing
          395   S5
       213349   FIBRINOGEN
S6         52   S S5 AND FIBRINOGEN

?  rd
Processing
Processing
Processing
Processing
Processing
Processing
Processing
Processing
Processing
Processing
Processing
Processing
Processing
>>>W:  Duplicate detection is not supported for File 393.
Records from unsupported files will be retained in the RD set.
S7         22   RD  (UNIQUE ITEMS)

?  t s7/medium,k/1-22
>>>W:  KWIC option is not available in file(s): 399
 7/K/1 (Item 1 from file: 5)  Links
   Fulltext available through:   USPTO Full Text Retrieval Options
Biosis Previews(R)
(c) 2007 The Thomson Corporation. All rights reserved.
0019555755   Biosis No.: 200700215496
A panel of monoclonal antibodies recognizing the Staphylococcus epidermidis
```

fibrinogen-binding MSCRAMM SdrG

Author: Hall Andrea E; Patel Pratiksha R; Domanski Paul J; Prater Bradley D; Gorovits Elena L; Syribeys Peter J; Vernachio John H; Patti Joseph M; Hutchins Jeff T (Reprint)
Author Address: Inhibitex Inc, 9005 Westside Pkwy, Alpharetta, GA 30004 USA**USA
Author E-mail Address: jhutchins@inhibitex.com
Journal: Hybridoma 26 (1): p 28-34 FEB 2007 2007
ISSN: 1554-0014
Document Type: Article
Record Type: Abstract
Language: English
A panel of monoclonal antibodies recognizing the Staphylococcus epidermidis fibrinogen-binding MSCRAMM SdrG

Abstract: ...stage contributing to the pathogenesis of this bacteria is the initial adherence to host tissue. SdrG is a cell-wall-anchored fibrinogen-binding adhesin of S. epidermidis that has been shown to be necessary for bacterial binding to fibrinogen-coated foreign bodies, such as catheters. Here we report the generation and characterization of a panel of monoclonal antibodies (MAbs) directed against this S. epidermidis virulence factor. Through the use of multiple in... ...that may prove to be beneficial in studies that address the precise biologic role of SdrG.
DESCRIPTORS:
Chemicals & Biochemicals: fibrinogen; ... ...monoclonal antibody... ...SdrG

>>>W: KWIC option is not available in file(s): 399
7/K/2 (Item 2 from file: 5) Links
Fulltext available through: American Society for Microbiology custom link
USPTO Full Text Retrieval Options
Biosis Previews(R)

18943764 Biosis No.: 200600289159
Human immunoglobulin G recognizing fibrinogen-binding surface proteins is protective against both Staphylococcus aureus and Staphylococcus epidermidis infections in vivo

Author: Vernachio John H (Reprint); Bayer Arnold S; Ames Brenda; Bryant Dawn; Prater Bradley D; Syribeys Peter J; Gorovits Elena L; Patti Joseph M
Author Address: Inhibitex Inc, 9005 Westside Pkwy, Alpharetta, GA 30004 USA**USA
Author E-mail Address: jvernachio@inhibitex.com
Journal: Antimicrobial Agents and Chemotherapy 50 (2): p 511-518 FEB 2006 2006
ISSN: 0066-4804
Document Type: Article
Record Type: Abstract
Language: English
Human immunoglobulin G recognizing fibrinogen-binding surface proteins is protective against both Staphylococcus aureus and Staphylococcus epidermidis infections in vivo

Abstract: A human donor-selected immunoglobulin G for intravenous injection (IGIV) product with elevated titers against the staphylococcal fibrinogen-binding MSCRAMM proteins ClfA and SdrG (INH-A21) was tested in vitro and in vivo. INH-A21 contained a significantly increased ability to inhibit the fibrinogen-binding activity of recombinant forms of both ClfA and SdrG. Evaluation of the opsonizing potential of INH-A21 was evaluated using fluorescently labeled bacteria; this...
DESCRIPTORS:
Chemicals & Biochemicals: ...immunoglobulin G... ...SdrG; ... ...fibrinogen-binding surface proteins

>>>W: KWIC option is not available in file(s): 399
7/K/3 (Item 3 from file: 5) Links

Fulltext available through: USPTO Full Text Retrieval Options
Biosis Previews(R)

18192570 Biosis No.: 200500098483
A fibrinogen-binding protein of Staphylococcus lugdunensis

Author: Nilsson Martin; Bjerketorp Joakim; Guss Bengt; Frykberg Lars (Reprint)
Author Address: Dept Microbiol, Swedish Univ Agr Sci, POB 7025, SE-75007, Uppsala, Sweden** Sweden
Author E-mail Address: lars.frykberg@mikrob.slu.se
Journal: FEMS Microbiology Letters 241 (1): p 87-93 December 1, 2004 2004
Medium: print
ISSN: 0378-1097
Document Type: Article
Record Type: Abstract
Language: English
A fibrinogen-binding protein of Staphylococcus lugdunensis

Abstract: A gene called fbl, encoding a Staphylococcus lugdunensis fibrinogen -binding protein, was identified by phage display. The encoded protein, Fbl, is a member of the Sdr-family, a group of staphylococcal cell surface proteins containing a characteristic serine-aspartate repeat region. The fibrinogen-binding domain was mapped to 313 amino acids, and shows, 62% identity to the corresponding region in clumping factor (ClfA) from Staphylococcus aureus. Anti-serum against ClfA cross-reacted with Fbl, and blocked S. lugdunensis adherence to fibrinogen. Twelve clinical isolates of S. lugdunensis analysed by Southern blot all had an fbl-like...

DESCRIPTORS:
Chemicals & Biochemicals: fibrinogen; ... ...fibrinogen-binding protein

>>>W: KWIC option is not available in file(s): 399
7/K/4 (Item 4 from file: 5) Links
Fulltext available through: USPTO Full Text Retrieval Options
Biosis Previews(R)

18024813 Biosis No.: 200400395602
beta2-integrins mediate a novel form of chemoresistance in cyclohexiimide-induced U937 apoptosis

Author: Wu R-C; Wang Z (Reprint); Liu M-J; Chen D-F; Yue X-S
Author Address: Dept Biol Sci and Biotechnol, Tsing Hua Univ, Beijing, 100084, China**China
Author E-mail Address: zwang@tsinghua.edu.cn
Journal: CMLS Cellular and Molecular Life Sciences 61 (16): p 2071-2082 August 2004 2004
Medium: print
ISSN: 1420-682X
Document Type: Article
Record Type: Abstract
Language: English

Abstract: ...leukaemic cell line U937, a novel form of chemoresistance, which we termed sudden drug resistance (SDR), was identified using Hoechst33258 staining, Western blott and DNA Ladder. CHXhigh (10-100 mug/ml ... ...inhibited by short-term preincubation with CHXlow (2.5 mug/ml). Unlike typical multidrug resistance, SDR is not caused by reduced drug accumulation or altered protein expression, and may be associated... ...adhesion has been suggested to influence cell survival and prevent apoptosis. EDTA, or anti-CD18 monoclonal antibody, but not EGTA, acetylsalicylic acid or RGDS tetrapeptide, abrogated this homotypic aggregation and greatly increased CHX-induced apoptosis in a time-dependent manner, while fibrinogen and soluble intercellular adhesion molecule-1 exerted opposite effects. These results establish that beta2-integrin engagement is a key mediator of SDR, although it may

be non-exclusive. This finding supplements the classical basis of chemoresistance and...
DESCRIPTORS:
Chemicals & Biochemicals: ...anti-CD18 monoclonal antibody...
Miscellaneous Terms: Concept Codes: sudden drug resistance {SDR}

>>>W: KWIC option is not available in file(s): 399
7/K/5 (Item 5 from file: 5) Links
Fulltext available through: USPTO Full Text Retrieval Options
Biosis Previews(R)

17564571 Biosis No.: 200300519934
Methicillin-resistant Staphylococcus aureus isolates carrying pls invade host cells less efficiently than pls-negative MRSA isolates.

Author: Sinha B (Reprint); Juuti K; Werbick C (Reprint); Kuusela P; Peters G (Reprint)
Author Address: Institute of Medical Microbiology, University Hospital of Muenster, Muenster, Germany**Germany
Journal: Abstracts of the General Meeting of the American Society for Microbiology 103 p B-207 2003 2003
Medium: cd-rom
Conference/Meeting: 103rd American Society for Microbiology General Meeting Washington, DC, USA May 18-22, 2003; 20030518
Sponsor: American Society for Microbiology
ISSN: 1060-2011 _(ISSN print)
Document Type: Meeting; Meeting Abstract
Record Type: Abstract
Language: English

Abstract: ...MSSA isolates. Pls (plasmin-sensitive) is a cell wall-anchored surface protein, belonging to the Sdr family of adhesins. Since adherence of pls-positive MRSA isolates to immobilized IgG, fibrinogen and Fn is reduced, we tested, whether this is also true for cellular invasiveness. Methods...
DESCRIPTORS:
Chemicals & Biochemicals: IgG {immunoglobulin G...

>>>W: KWIC option is not available in file(s): 399
7/K/6 (Item 6 from file: 5) Links
Biosis Previews(R)

17309113 Biosis No.: 200300277832
MSCRAMM(R) protein mAb protects against S. epidermidis central venous catheter induced infection.

Author: Vernachio J (Reprint); Bryant D (Reprint); Hall A (Reprint); Patel P (Reprint); Domanski P (Reprint); Syribeys P (Reprint); Gorovits E (Reprint) ; Wang J (Reprint); Robbins J (Reprint); Hutchins J (Reprint); Patti J (Reprint)
Author Address: Inhibitex, Inc., Alpharetta, GA, USA**USA
Journal: Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy 42 p 32 2002 2002
Medium: print
Conference/Meeting: American Society for Microbiology (ASM) Annual Meeting on Infectious Disaease San Diego, CA, USA September 27-30, 2002; 20020927
Sponsor: American Society for Microbiology
Document Type: Meeting; Meeting Abstract
Record Type: Abstract
Language: English

Abstract: ...both a reduction in the incidence and severity of disease. We have demonstrated that a monoclonal antibody (mAb) against the MSCRAMM(R) protein, SdrG,

inhibits the binding to human fibrinogen in vitro and also provides significant protection against methicillin resistant S. epidermidis (MRSE) challenge in...
...infection model. Methods: Clinical efficacy was evaluated in a rat model of CVC-associated infection. SdrG mAb 59-59 (n=10) and a control mAb (n=13) were administered IV. 24... ...were infected (13/13). Conclusions: These data clearly demonstrate that a single infusion with a SdrG mAb can significantly prevent catheter associated MRSE bacteremia and subsequent hematogenous dissemination to target organs.
DESCRIPTORS:
Chemicals & Biochemicals: ...monoclonal antibodies... ...MSCRAMM protein monoclonal antibody

>>>W: KWIC option is not available in file(s): 399
7/K/7 (Item 7 from file: 5) Links
Biosis Previews(R)

16972468 Biosis No.: 200200565979
Prevention of experimental Staphylococcus epidermidis (SE) endocarditis (IE) by passive immunotherapy with INH-A00021, a human IgG directed against staphylococcal fibrinogen-binding proteins

Author: Kupferwasser L I (Reprint); Prater B; Wang J; Ruckstuhl M J; Lee K; Gast D; Adams D; Patti J M; Bayer A S (Reprint)
Author Address: Harbor-UCLA Res. and Ed. Inst., Torrance, CA, USA**USA
Journal: Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy 41 p 278 2001 2001
Medium: print
Conference/Meeting: 41st Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy Chicago, Illinois, USA September 22-25, 2001; 20010922
Document Type: Article; Meeting
Record Type: Abstract
Language: English
...SE) endocarditis (IE) by passive immunotherapy with INH-A00021, a human IgG directed against staphylococcal fibrinogen-binding proteins

Abstract: Background: SE is a major cause of endovascular infections, utilizing adhesins such as the fibrinogen-binding adhesin, SdrG, to bind to sites of endovascular damage. Purpose: INH-A00021 is a donor-selected, plasma-derived hyperimmune globulin containing elevated levels of IgG against the staphylococcal fibrinogen-binding proteins, SdrG, and ClfA. This study evaluated the efficacy of INH-A00021 in attenuating experimental SE IE... ...p=0.0006). Also, the extent of bacteremia was significantly lower in animals receiving anti-SdrG, when compared to controls (p<0.01). Results of quantitative tissue cultures (mean log10CFU/g...
DESCRIPTORS:
Chemicals & Biochemicals: ...IgG {immunoglobulin G... ...SdrG--...
...fibrinogen-binding adhesion... ...staphylococcal fibrinogen-binding proteins

>>>W: KWIC option is not available in file(s): 399
7/K/8 (Item 8 from file: 5) Links
Fulltext available through: USPTO Full Text Retrieval Options
Biosis Previews(R)

15411492 Biosis No.: 200000129805
A bone sialoprotein-binding protein from Staphylococcus aureus: A member of the staphylococcal Sdr family

Author: Tung Hui-shan; Guss Bengt; Hellman Ulf; Persson Lena; Rubin Kristofer; Ryden Cecilia (Reprint)
Author Address: Department of Medical Biochemistry and Microbiology, Uppsala University, BMC, SE-751 23, Uppsala, Sweden**Sweden

Journal: Biochemical Journal 345 (3): p 611-619 Feb. 1, 2000 2000
Medium: print
ISSN: 0264-6021
Document Type: Article
Record Type: Abstract
Language: English
A bone sialoprotein-binding protein from Staphylococcus aureus: A member of the staphylococcal Sdr family

Abstract: ...acids, called BSP-binding protein (Bbp), which displays similarity to recently described proteins of the Sdr family from S. aureus. SdrC, SdrD and SdrE encode putative cell-surface proteins with no described ligand specificity. Bbp also shows similarity to a fibrinogen -binding protein from S. epidermidis called Fbe. A serine-aspartic acid repeat sequence was found close to the cell-wall-anchoring Leu... ...protein bound radiolabelled native BSP, and inhibited the binding of radiolabelled BSP to staphylococcal cells. Serum from patients suffering from bone and joint infection contained antibodies that reacted with the fusion...
DESCRIPTORS:
Chemicals & Biochemicals: Sdr;

>>>W: KWIC option is not available in file(s): 399
7/K/9 (Item 1 from file: 34) Links
Fulltext available through: American Society for Microbiology custom link
USPTO Full Text Retrieval Options
SciSearch(R) Cited Ref Sci

09577298 Genuine Article#: 423CT No. References: 51
Expression of pls, a gene closely associated with the mecA gene of methicillin-resistant Staphylococcus aureus, prevents bacterial adhesion in vitro

Author: Savolainen K (REPRINT) ; Paulin L; Westerlund-Wikstrom B; Foster TJ; Korhonen TK; Kuusela P
Corporate Source: Univ Helsinki,Div Gen Microbiol, Dept Biosci,POB 56/FIN-00014 Helsinki//Finland/ (REPRINT); Univ Helsinki,Div Gen Microbiol, Dept Biosci,FIN-00014 Helsinki//Finland/; Univ Helsinki,Inst Biotechnol,FIN-00014 Helsinki//Finland/; Univ Helsinki,Haartman Inst, Dept Bacteriol & Immunol,FIN-00014 Helsinki//Finland/; Univ Helsinki,Cent Hosp, HUCH Lab Diagnost, Div Clin Microbiol,Helsinki//Finland/; Univ Dublin Trinity Coll,Moyne Inst Prevent Med, Dept Microbiol,Dublin 2//Ireland/
Journal: INFECTION AND IMMUNITY , 2001 , V 69 , N5 (MAY) , P 3013-3020
ISSN: 0019-9567 Publication date: 20010500
Publisher: AMER SOC MICROBIOLOGY , 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
Language: English Document Type: ARTICLE (ABSTRACT AVAILABLE)
Abstract: ...distinct repeat regions, one of which was a serine-aspartate repeat characteristic of the Clf-Sdr family of surface proteins in staphylococci, The lengths of the repeat regions varied in different... ...digested DNA. A pls mutant constructed by allele replacement adhered well to immobilized fibronectin and immunoglobulin e, in contrast to the parental strain, suggesting that Pls could have a role in...
Identifiers-- ...FIBRINOGEN-BINDING PROTEIN; NUCLEOTIDE-SEQUENCE; CLUMPING FACTOR; INSERTIONAL INACTIVATION; ESCHERICHIA-COLI; REPEAT REGION; FIBRONECTIN; CLONING; DNA

>>>W: KWIC option is not available in file(s): 399
7/K/10 (Item 2 from file: 34) Links
Fulltext available through: USPTO Full Text Retrieval Options
SciSearch(R) Cited Ref Sci

02147492 Genuine Article#: KE378 No. References: 43
INHIBITION OF PLATELET-ADHESION TO FIBRIN(OGEN) IN FLOWING WHOLE-BLOOD BY ARG-GLY-ASP AND FIBRINOGEN GAMMA-CHAIN CARBOXY TERMINAL PEPTIDES

Author: HANTGAN RR; ENDENBURG SC; CAVERO I; MARGUERIE G; UZAN A; SIXMA JJ; DEGROOT

PG
Corporate Source: WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT BIOCHEM,MED CTR BLVD/WINSTON SALEM//NC/27157; UNIV UTRECHT,DEPT HEMATOL/UTRECHT//NETHERLANDS/; RHONE POULENC RORER RD/VITRY//FRANCE/; INSERM,U127,HEMATOL LAB/GRENOBLE//FRANCE/
Journal: THROMBOSIS AND HAEMOSTASIS , 1992 , V 68 , N6 (DEC 7) , P 694-700
ISSN: 0340-6245
Language: ENGLISH Document Type: ARTICLE (Abstract Available)
...OF PLATELET-ADHESION TO FIBRIN(OGEN) IN FLOWING WHOLE-BLOOD BY ARG-GLY-ASP AND FIBRINOGEN GAMMA-CHAIN CARBOXY TERMINAL PEPTIDES
Abstract: We have employed synthetic peptides with sequences corresponding to the integrin receptor-recognition regions of fibrinogen as inhibitors of platelet aggregation and adhesion to fibrinogen and fibrin-coated surfaces in flowing whole blood, using a rectangular perfusion chamber at wall... ...1,300 s-1. D-RGDW caused substantial inhibition of platelet aggregation and adhesion to fibrinogen and fibrin at both shear rates, although it was least effective at blocking platelet adhesion... ...300 s-1. RGDS was a weaker inhibitor, and produced a biphasic dose-response curve; SDRG was inactive. HHLGGAKQAGDV partially inhibited platelet aggregation and adhesion to fibrin(ogen) at both shear ...
Identifiers-- ...GLYCOPROTEIN-IIB-IIIA; VONWILLEBRAND-FACTOR; MONOCLONAL -ANTIBODIES; ARTIFICIAL SURFACES; BINDING; RECEPTOR; SUBENDOTHELIUM; COMPLEX; CELLS; FIBRONECTIN
Research Fronts: 91-2339 004 (PLATELET GLYCOPROTEIN-IIB-IIIA COMPLEX; FIBRINOGEN RECEPTOR ANTAGONIST; ANTIPLATELET ARG-GLY-ASP-CONTAINING PEPTIDE; SNAKE-VENOM PROTEIN ECHISTATIN)
 91-5876 001...

>>>W: KWIC option is not available in file(s): 399
 7/K/11 (Item 1 from file: 50) Links
   Fulltext available through: USPTO Full Text Retrieval Options
CAB Abstracts

0008126189 CAB Accession Number: 20013167686
Fibrinogen - and von Willebrand factor-binding proteins in staphylococci.

Nilsson, M.
Department of Microbiology, Swedish University of Agricultural Sciences, Box 7025, S-750 07 Uppsala, Sweden.
Acta Universitatis Agriculturae Sueciae - Agraria (265): p.115
Publication Year: 2001
ISSN: 1401-6249
Publisher: Sveriges Lantbruksuniversitet (Swedish University of Agricultural Sciences) Uppsala , Sweden
ISBN: 91-576-5791-2
Language: English Record Type: Abstract
Document Type: Thesis
Fibrinogen - and von Willebrand factor-binding proteins in staphylococci.
... genes, isolated from coagulase-negative staphylococci (CoNS) associated with human infections, and their corresponding proteins. Fbe and Fbl are the main fibrinogen (Fg)-binding proteins of Staphylococcus epidermidis and S. lugdunensis , respectively. Both proteins are members of the Sdr (SD-repeat containing protein) family, a subgroup of cell surface proteins in staphylococci with a... ... less perfect, tandemly repeated serine and aspartate residues. Sequence comparisons in the binding regions between Fbe and Fbl revealed low mutual similarity. However, Fbl is relatively conserved (63% identity) in the binding region compared to clumping factor A (ClfA), the prototype Sdr protein from S. aureus . The third gene, vWbl , encodes a putative von Willebrand factor (vWf... ... an overall organization, that is characteristic for cell surface proteins in staphylococci. The importance of Fbe, Fbl and vWbl for their respective organisms during the infection process is not known, but ... ... to extracellular matrix or plasma-coated biomaterials. Separate recombinant constructs, comprising the binding regions of Fbe and Fbl or separate antibodies directed against the binding regions of the proteins, were able... ... the adherence of S. epidermidis and S. lugdunensis , respectively, to immobilized

Fg. The presence of fbe, fbl and vwbl genes is very common in clinical isolates of the respective species. In... ... these experiments, vWbp immobilized on a Sepharose-column was used to purify vWf from human serum. The gene vWb was present in all tested strains of S. aureus .

Descriptors: ...fibrinogen;

>>>W: KWIC option is not available in file(s): 399
7/K/12 (Item 1 from file: 71) Links
Fulltext available through: USPTO Full Text Retrieval Options

02747070 2004224218
betaSUB2-integrins mediate a novel form of chemoresistance in cycloheximide-induced U937 apoptosis

Wu R.-C.; Wang Z.; Liu M.-J.; Chen D.-F.; Yue X.-S.
Address: Z. Wang, Dept. of Biol. Sci. and Biotech., Tsinghua University, Beijing , China
Email: zwang@tsinghua.edu.cn
Journal : Cellular and Molecular Life Sciences , 61/16 (2071-2082) , 2004 , Switzerland
CODEN: CMLSF
ISSN: 1420-682X
Document Type: Article
Languages: English Summary Languages: English
No. of References: 48

DESCRIPTORS:
Apoptosis; Cycloheximide; U937 cell; betaSUB2-integrin; Drug resistance; PI-3K

CLASSIFICATION CODE AND DESCRIPTION:
Modlecular Sequence Databank Number: 87.2.1.5 - CANCER RESEARCH / TUMOUR BIOLOGY / Cellular Biology and Biochemistry / Immortalisation, senescence and apoptosis
87.4.1.15 - CANCER RESEARCH / TREATMENT / Chemotherapy / Resistance
87.4.11 - CANCER RESEARCH / TREATMENT / Treatment Monitoring and Evaluation

...leukaemic cell line U937, a novel form of chemoresistance, which we termed sudden drug resistance (SDR), was identified using Hoechst33258 staining, Western blott and DNA Ladder. CHXSUPhigh (10-100 mug/ml... ...inhibited by short-term preincubation with CHXSUBlow (2.5 mug/ml). Unlike typical multidrug resistance, SDR is not caused by reduced drug accumulation or altered protein expression, and may be associated... ...has been suggested to influence cell survival and prevent apoptosis. EDTA, or anti-CD 18 monoclonal antibody, but not EGTA, acetylsalicylic acid or RGDS tetrapeptide, abrogated this homotypic aggregation and greatly increased CHX-induced apoptosis in a time-dependent manner, while fibrinogen and soluble intercellular adhesion molecule-1 exerted opposite effects. These results establish that betaSUB2-integrin engagement is a key mediator of SDR, although it may be non-exclusive. This finding supplements the classical basis of chemoresistance and...

>>>W: KWIC option is not available in file(s): 399
7/K/13 (Item 1 from file: 155) Links
Fulltext available through: USPTO Full Text Retrieval Options

15223135 PMID: 15583173
Protein FOG--a streptococcal inhibitor of neutrophil function.

Johansson Helena M; Morgelin Matthias; Frick Inga-Maria
Department of Cell and Molecular Biology, Section for Clinical and Experimental

Infectious Medicine, BMC, B14, Lund University, S-221 84 Lund, Sweden.
Microbiology (Reading, England) (England) Dec 2004 , 150 (Pt 12) p4211-21 ,
 ISSN: 1350-0872--Print Journal Code: 9430468
Publishing Model Print
Document type: Journal Article; Research Support, Non-U.S. Gov't
Languages: ENGLISH
Main Citation Owner: NLM
Record type: MEDLINE; Completed
...of group G streptococci (GGS) form aggregates when grown in vitro. Aggregating strains interact with fibrinogen, and this study reports the isolation of a novel self-associating and fibrinogen-binding protein of GGS, denoted protein FOG. Sequencing of the fog gene revealed structural similarity... ...of GGS express protein G, a protein known to interact with the constant region of immunoglobulin G and albumin. Surprisingly, a clinical isolate expressing protein G, but lacking protein FOG, was... ...negative strain from being killed. The antibactericidal property of protein FOG is dependent on its fibrinogen-binding activity. Thus, in plasma, FOG precipitates fibrinogen, and when added to whole blood, protein FOG triggers the formation of visible aggregates comprising fibrinogen and neutrophils that are disabled in their killing of the bacteria. Moreover, the results emphasize...
Descriptors: *Bacterial Proteins--metabolism--ME; *Blood--microbiology--MI; *Carrier Proteins--metabolism--ME; *Fibrinogen--metabolism--ME; *Neutrophils --immunology--IM; *Streptococcus--growth and development--GD
Chemical Name: Bacterial Proteins; Carrier Proteins; Fbe protein, bacteria; Fibrinogen

>>>W: KWIC option is not available in file(s): 399
 7/K/14 (Item 1 from file: 393) Links
Beilstein Database - Abstracts

Beilstein Abstract Id: 6577659
Title: Human Immunoglobulin G Recognizing Fibrinogen-Binding Surface Proteins Is Protective against both Staphylococcus aureus and Staphylococcus epidermidis Infections In Vivo
Document Type: Journal Record Type: Abstract
Author: Vernachio, John H.; Bayer, Arnold S.; Ames, Brenda; Bryant, Dawn; Prater, Bradley D.; Syribeys, Peter J.; Gorovits, Elena L.; Patti, Joseph M.
Citation: Antimicrob. Agents & Chemother. (2006) Series: 50-2, 511 - 518 CODEN: AMACCQ Language: English
Abstract Language: English
Title: Human Immunoglobulin G Recognizing Fibrinogen-Binding Surface Proteins Is Protective against both Staphylococcus aureus and Staphylococcus epidermidis Infections In Vivo
Abstract: A human donor-selected immunoglobulin G for intravenous injection (IGIV) product with elevated titers against the staphylococcal fibrinogen-binding MSCRAMM proteins ClfA and SdrG (INH-A21) was tested in vitro and in vivo. INH-A21 contained a significantly increased ability to inhibit the fibrinogen-binding activity of recombinant forms of both ClfA and SdrG. Evaluation of the opsonizing potential of INH-A21 was evaluated using fluorescently labeled bacteria; this...

>>>W: KWIC option is not available in file(s): 399
 7/K/15 (Item 2 from file: 393) Links
Beilstein Database - Abstracts

Beilstein Abstract Id: 6471865
Title: beta 2 -integrins mediate a novel form of chemoresistance in cyclohexiimide-induced U937 apoptosis
Document Type: Journal Record Type: Abstract
Author: Wu, R.-C.; Wang, Z.; Liu, M.-J.; Chen, D.-F.; Yue, X.-S.
Citation: Cell. Mol. Life Sci (2004) Series: 61-16, 2071 - 2082 CODEN: CMLSFI
Language: English

Abstract Language: English
Keywords: apoptosis; cycloheximide; U937 cell; Beta 2 -integrin; drug resistance; PI-3K
Abstract: ... leukaemic cell line U937, a novel form of chemoresistance, which we termed sudden drug resistance (SDR), was identified using Hoechst33258 staining, Western blott and DNA Ladder. CHX high (10-100 mu... ... short-term preincubation with CHX low (2.5 mu g/ml). Unlike typical multidrug resistance, SDR is not caused by reduced drug accumulation or altered protein expression, and may be associated... ... adhesion has been suggested to influence cell survival and prevent apoptosis. EDTA, or anti-CD18 monoclonal antibody, but not EGTA, acetylsalicylic acid or RGDS tetrapeptide, abrogated this homotypic aggregation and greatly increased CHX-induced apoptosis in a time-dependent manner, while fibrinogen and soluble intercellular adhesion molecule-1 exerted opposite effects. These results establish that beta 2 -integrin engagement is a key mediator of SDR, although it may be non-exclusive. This finding supplements the classical basis of chemoresistance and...

>>>W: KWIC option is not available in file(s): 399
7/K/16 (Item 1 from file: 399) Links
CA SEARCH(R)

144348882 CA: 144(19)348882p PATENT
Immunogenic composition comprising a mixture of staphylococcal antigens and uses as vaccines
Inventor (Author): Castado, Cindy; Lecrenier, Nicolas Pierre Fernand; Neyt, Cecile Anne; Poolman, Jan
Location: Belg.
Assignee: GlaxoSmithKline Biologicals S.A.
Patent: PCT International ; WO 200632472 A2 Date: 20060330
Application: WO 2005EP10184 (20050920) *GB 200421082 (20040922) *GB 200421078 (20040922) *GB 200421081 (20040922) *GB 200421079 (20040922) *GB 20053143 (20050215)

Pages: 132 pp.
CODEN: PIXXD2
Language: English
Patent Classifications:
Class: A61K-000/A
Designated Countries: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KM; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; LY; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NG; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RU; SC; SD; SE; SG; SK; SL; SM; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; YU; ZA; ZM
Designated Regional: AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LT; LU; LV; MC; NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG; BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM

>>>W: KWIC option is not available in file(s): 399
7/K/17 (Item 2 from file: 399) Links
CA SEARCH(R)

141348821 CA: 141(21)348821f PATENT
Staphylococcus epidermidis-derived hyperimmune serum reactive antigens and encoding nucleic acids for diagnosis and treatment of bacterial infection and for antagonist screening
Inventor (Author): Meinke, Andreas; Min, Bui Duc; Nagy, Eszter
Location: Austria
Assignee: Intercell AG
Patent: PCT International ; WO 200487746 A2 Date: 20041014
Application: WO 2004EP3398 (20040331) *EP 2003450078 (20030331)

Pages: 196 pp.
CODEN: PIXXD2
Language: English
Patent Classifications:
  Class: C07K-014/00A
Designated Countries: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RU; SC; SD; SE; SG; SK; SL; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; YU; ZA; ZM; ZW
Designated Regional: BW; GH; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IT; LU; MC; NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

>>>W: KWIC option is not available in file(s): 399
 7/K/18 (Item 3 from file: 399) Links
CA SEARCH(R)

139259972 CA: 139(17)259972x PATENT
Monoclonal and polyclonal antibodies recognizing coagulase-negative staphylococcal proteins
Inventor (Author): Patti, Joseph M.; Hutchins, Jeff T.; Hall, Andrea; Domanski, Paul; Patel, Pratisksha; Hook, Magnus; Robbins, Jeff; Vernachio, John; Bowden, Maria G.
Location: USA
Assignee: Inhibitex, Inc.; The Texas A & M University System
Patent: PCT International ; WO 200376470 A1 Date: 20030918
Application: WO 2003US6415 (20030305) *US PV361324 (20020305)
Pages: 72 pp.
CODEN: PIXXD2
Language: English
Patent Classifications:
  Class: C07K-016/00A; C07K-001/00B; C07K-002/00B; C07H-021/04B; A61K-039/395B; A61K-039/40B; A61K-039/00B; A61K-039/09B; A61K-039/085B
Designated Countries: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; OM; PH; PL; PT; RO; RU; SC; SD; SE; SG; SK; SL; TJ; TM; TN; TR; TT; TZ; UA; UG; UZ; VC; VN; YU; ZA; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM
Designated Regional: GH; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZM; ZW; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IT; LU; MC; NL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

>>>W: KWIC option is not available in file(s): 399
 7/K/19 (Item 1 from file: 357) Links
  Fulltext available through: USPTO Full Text Retrieval Options
Derwent Biotech Res.

0420861 DBA Accession No.: 2007-06799
A panel of monoclonal antibodies recognizing the Staphylococcus epidermidis fibrinogen-binding MSCRAMM SdrG hybridoma cell culture for recombinant monoclonal antibody production

Author: HALL AE; PATEL PR; DOMANSKI PJ; PRATER BD; GOROVITS EL; SYRIBEYS PJ; VERNACHIO JH; PATTI JM; HUTCHINS JT
Corporate Affiliate: Inhibitex Inc
Corporate Source: Hutchins JT, Inhibitex Inc, 9005 Westside Pkwy, Alpharetta, GA 30004 USA
Journal: HYBRIDOMA (26, 1, 28-34) 2007

ISSN: 1554-0014
Language: English
A panel of monoclonal antibodies recognizing the Staphylococcus epidermidis fibrinogen-binding MSCRAMM SdrG hybridoma cell culture for recombinant monoclonal antibody production
Abstract: ...stage contributing to the pathogenesis of this bacteria is the initial adherence to host tissue. SdrG is a cell-wall-anchored fibrinogen-binding adhesin of S. epidermidis that has been shown to be necessary for bacterial binding to fibrinogen-coated foreign bodies, such as catheters. Here we report the generation and characterization of a panel of monoclonal antibodies (MAbs) directed against this S. epidermidis virulence factor. Through the use of multiple in... ...that may prove to be beneficial in studies that address the precise biologic role of SdrG. (7 pages)
Descriptors: Staphylococcus epidermidis fibrinogen-binding MSCRAMM SdrG -specific recombinant monoclonal antibody prep., purification, characterization, plasmid-mediated gene transfer, expression in Lactococcus lactis, hybridoma, mouse immunization...

>>>W: KWIC option is not available in file(s): 399
7/K/20 (Item 2 from file: 357) Links
Fulltext available through: USPTO Full Text Retrieval Options
Derwent Biotech Res.

0358809 DBA Accession No.: 2005-04513
A fibrinogen-binding protein of Staphylococcus lugdunensis identification and production of a recombinant fibrinogen binding protein from Staphylococcus lugdunensis using phage display and recombinant technology

Author: NILSSON M; BJERKETORP J; GUSS B; FRYKBERG L
Corporate Affiliate: Swedish Univ Agr Sci
Corporate Source: Frykberg L, Swedish Univ Agr Sci, Dept Microbiol, POB 7025, SE-75007 Uppsala, Sweden
Journal: FEMS MICROBIOLOGY LETTERS (241, 1, 87-93) 2004
ISSN: 0378-1097
Language: English
A fibrinogen-binding protein of Staphylococcus lugdunensis identification and production of a recombinant fibrinogen binding protein from Staphylococcus lugdunensis using phage display and recombinant technology
Abstract: AUTHOR ABSTRACT - A gene called fbl, encoding a Staphylococcus lugdunensis fibrinogen-binding protein, was identified by phage display. The encoded protein, Fbl, is a member of the Sdr-family, a group of staphylococcal cell surface proteins containing a characteristic serine-aspartate repeat region. The fibrinogen-binding domain was mapped to 313 amino acids, and shows, 62% identity to the corresponding region in clumping factor (ClfA) from Staphylococcus aureus. Anti- serum against ClfA cross-reacted with Fbl, and blocked S. lugdunensis adherence to fibrinogen. Twelve clinical isolates of S. lugdunensis analysed by Southern blot all had an fbl-like...
Descriptors: Staphylococcus lugdunensis, recombinant fibrinogen binding protein, prep, isol., characterization, phage display, fbl gene identification, Southern blot bacterium surface display...

>>>W: KWIC option is not available in file(s): 399
7/K/21 (Item 3 from file: 357) Links
Derwent Biotech Res.

0324377 DBA Accession No.: 2003-25518 PATENT
New antibody recognizing a Staphylococcus epidermidis protein comprising SdrG N1N2N3, SdrG N2N3 or SdrGTR2 useful for preparing a composition for treating or preventing a coagulase-negative Staphylococcal infection chimeric antibody, humanized antibody, monoclonal antibody and single chain antibody production for vaccine, gene therapy and therapy

Author: PATTI J M; HUTCHINS J T; HALL A; DOMANSKI P; PATEL P; HOOK M; ROBBINS J; VERNACHIO J; BOWDEN M G
Patent Assignee: INHIBITEX INC; UNIV TEXAS A and M SYSTEM 2003
Patent Number: WO 200376470 Patent Date: 20030918 WPI Accession No.: 2003-722324 (200368)
Priority Application Number: US 361324 Application Date: 20020305
National Application Number: WO 2003US6415 Application Date: 20030305
Language: English
New antibody recognizing a Staphylococcus epidermidis protein comprising SdrG N1N2N3, SdrG N2N3 or SdrGTR2 useful for preparing a composition for treating or preventing a coagulase-negative Staphylococcal infection chimeric antibody, humanized antibody, monoclonal antibody and single chain antibody production for vaccine, gene therapy and therapy
Abstract: DERWENT ABSTRACT: NOVELTY - An isolated antibody (I) that recognizes a protein from Staphylococcus epidermidis comprising SdrG N1N2N3, SdrG N2N3 or SdrGTR2, is new. DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for: (1) isolated... ...treating or preventing a coagulase-negative Staphylococcal infection; (7) an isolated S. epidermidis protein comprising SdrG N1N2N3, SdrG N2N3 or SdrGTR2; (8) eliciting an immunogenic reaction in a human or animal; (9) a... ...epidermidis protein; and (10) an isolated nucleic acid sequence encoding an S. epidermidis protein comprising SdrG N1N2N3, SdrG N2N3 or SdrGTR2. BIOTECHNOLOGY - Preferred Antibody: The antibody (I) is selected from chimeric, murine, humanized or human monoclonal antibodies. (I) is a single chain monoclonal antibody. (I) binds to the S. epidermidis SdrG protein. (I) recognizes an amino acid sequence selected from the fully defined sequence comprising 560... ...or 951 (S6) base pairs, respectively, as given in the specification. (II) and (III) are monoclonal antibodies. Preferred Kit: The kit comprises means for detecting binding by the antibody, which comprises a detectable label linked to the antibody. Preferred Protein: The isolated S. epidermidis protein comprising SdrG N1N2N3, SdrG N2N3 or SdrGTR2 comprises an amino acid sequence selected from S1-S3 encoded by a ... ...Staphylococcal infection in a human or an animal and inhibits binding of Staphylococcal bacteria to fibrinogen, useful for preparing a composition for treating or preventing a coagulase-negative Staphylococcal infection. The monoclonal antibodies (II) and (III) comprising 1092 amino acids and 549 amino acids, respectively are also... ...for treating or preventing a coagulase-negative Staphylococcal infection. An isolated S. epidermidis protein comprising SdrG N1N2N3, SdrG N2N3 or SdrGTR2 is administered to a human or animal to elicit an immune reaction...
Descriptors: Staphylococcus sp. epidermis-specific chimeric antibody, humanized antibody, monoclonal antibody, single chain antibody prep., appl. vaccine, gene therapy, therapy antibody engineering antibody engineering protein...

>>>W: KWIC option is not available in file(s): 399
7/K/22 (Item 1 from file: 149) Links
TGG Health&Wellness DB(SM)

01988263 Supplier Number: 73924880 (USE FORMAT 7 OR 9 FOR FULL TEXT)
Whole genome sequencing of meticillin-resistant Staphylococcus aureus.

Kuroda, Makoto; Ohta, Toshiko; Uchiyama, Ikuo; Baba, Tadashi; Yuzawa, Harumi; Kobayashi, Ichizo; Cui, Longzhu; Oguchi, Akio; Aoki, Ken-ichi; Nagai, Yoshimi; Lian, JianQi; Ito, Teruyo; Kanamori, Mutsumi; Matsumaru, Hiroyuki; Maruyama, Atsushi; Murakami, Hiroyuki; Hosoyama, Akira; Mizutani-Ui, Yoko; Takahashi, Noriko K; Sawano, Toshihiko; Inoue, Ryu-ichi; Kaito, Chikara; Sekimizu, Kazuhisa; Hirakawa, Hideki; Kuhara, Satoru; Goto, Susumu; Yabuzaki, Junko; Kanehisa, Minoru; Yamashita, Atsushi; Oshima, Kenshiro; Furuya, Keiko; Yoshino, Chie; Shiba, Tadayoshi; Hattori, Masahira ; Ogasawara, Naotake; Hayashi, Hideo; Hiramatsu, Keiichi
The Lancet , 357 , 9264 , 1225
April 21 ,
2001
Publication Format: Magazine/Journal; Refereed

ISSN: 0099-5355
Language: English
Record Type: Fulltext; Abstract Target Audience: Professional
Word Count: 10338 Line Count: 01076

Descriptors: Staphylococcus aureus--Genetic aspects; Genetic recombination--Physiological aspects; Drug resistance--Genetic aspects
File Segment: HI File 149

...wall sorting signal in N315 and Mu50 genomes (table 4). These include seven known adhesins: fibrinogen-binding proteins ClfA, ClfB, and SdrC-D-E, and fibronectin-binding proteins FnbA and FnbB...

...to form clusters at several loci in the genome rather than being randomly distributed. The fibrinogen-binding proteins are characteristic in their possession of serine-aspartate repeats that precede the LPXTG...

...similar to Streptococcus pyogenes myosin-reactive protein,(30) which is known to react with the serum of patients with acute rheumatic fever. The other three open reading frames (SA1751, SA0841, and...Ryden C. A bone sialoprotein-binding protein from Staphylococcus aureus: a member of the staphylococcal Sdr family. Biochem J 2000; 345: 611-19.
(28) Schneewind O, Model P, Fischetti VA. Sorting...

haemolysin	SAS065	
Probable haemolysin		SA1973
g-haemolysin components		SA2207, 2208, 2209
Adhesins		
Ser-Asp rich fibrinogen-binding proteins		SA0742, 2423, 0519, 0520, 0521
Probable adhesin		SA0587
Possible extracellular matrix binding proteins		SA0744, 0745
Possible fibrinogen-binding proteins		SA1000, 1003, 1004
Probable extracellular matrix binding proteins		SA1267, 1268
Elastin-binding protein...		
...adhesion proteins	SA2459, 2460, 2461, 2462	
Others		
Myosin-crossreactive MHC class II-like protein		SA0102
Immunoglobulin G binding protein A		SA0107
Possible siderophore biosynthesis proteins		SA0116, 0117
Probable capsular polysaccharide		SA0126...
d-haemolysin	hld	
Probable haemolysin		
g-haemolysin components		hlgA, hlgC, hlgB
Adhesins		
Ser-Asp rich fibrinogen-binding proteins		clfA, clfB sdrC, sdrD, sdrE
Probable adhesin		
Possible extracellular matrix binding proteins		
Possible fibrinogen-binding proteins		
Probable extracellular matrix binding proteins		ebhA, ebhB
Elastin-binding protein		ebpS

Fibronectin-binding...

...Intercellular adhesion proteins icaA, icaD, icaB, icaC

Others
Myosin-crossreactive MHC class II-like protein
Immunoglobulin G binding protein A spa
Possible siderophore biosynthesis proteins
Probable capsular polysaccharide synthesis proteins
Capsular...

...toxin 1 SaPIn1/SaPIml
d-haemolysin
Probable haemolysin
g-haemolysin components

Adhesins
Ser-Asp rich fibrinogen-binding proteins
Probable adhesin
Possible extracellular matrix binding proteins
Possible fibrinogen-binding proteins
Probable extracellular matrix binding proteins
Elastin-binding protein
Fibronectin-binding proteins
Intercellular adhesion proteins

Others
Myosin-crossreactive MHC class II-like protein
Immunoglobulin G binding protein A
Possible siderophore biosynthesis proteins
Probable capsular polysaccharide synthesis proteins
Capsular polysaccharide...

...cells
Probable haemolysin Unknown
g-haemolysin components Destruction of blood cells

Adhesins
Ser-Asp rich fibrinogen
-binding proteins Cellular adhesion onto host tissues
Probable adhesin Cellular adhesion onto host tissues
Possible extracellular matrix binding proteins Cellular adhesion onto host tissues
Possible fibrinogen-binding proteins Unknown
Probable extracellular matrix binding proteins Unknown
Elastin-binding protein Cellular adhesion onto...

...infected tissues
Others
Myosin-crossreactive MHC class II-like protein Potential immune disorder in host
Immunoglobulin

G binding protein A	Potential immune disorder in host	
Possible siderophore biosynthesis proteins...		Iron uptake

STIC

RESULT 23 for SEQ ID NO: 16
ABP40469
ID ABP40469 standard; protein; 930 AA.
XX
AC ABP40469;
XX
DT 24-JUL-2002 (first entry)
XX
DE Staphylococcus epidermidis ORF amino acid sequence SEQ ID NO:5314.
XX
KW Staphylococcus epidermidis; open reading frame; ORF; bacterial infection;
KW antibacterial; gene therapy.
XX
OS Staphylococcus epidermidis.
XX
PN US6380370-B1.
XX
PD 30-APR-2002.
XX
PF 13-AUG-1998; 98US-00134001.
XX
PR 14-AUG-1997; 97US-0055779P.
PR 08-NOV-1997; 97US-0064964P.
XX
PA (GENO-) GENOME THERAPEUTICS CORP.
XX
PI Doucette-Stamm LA, Bush D;
XX
DR WPI; 2002-381255/41.
DR N-PSDB; ABN93014.
XX
PT Novel isolated nucleic acid encoding a Staphylococcus epidermis
PT polypeptide, useful for diagnosing and treating bacterial infections.
XX
PS Disclosure; SEQ ID NO 5314; 267pp; English.
XX
CC ABN90538 to ABN93374 represent Staphylococcus epidermidis open reading
CC frame (ORF) nucleic acid sequences which encode the amino acid sequences
CC given in ABP35124 to ABP37960. The S. epidermidis sequences have
CC antibacterial activity and can be used in gene therapy. The sequences can
CC also be used in the diagnosis and treatment of bacterial infections,
CC particularly S. epidermidis infections. The sequences can be used to
CC screen for compounds able to interfere with the S. epidermidis life cycle
CC or inhibit S. epidermidis infection. N.B. The sequence data for this
CC patent did not form part of the printed specification, but was obtained
CC in electronic format directly from the USPTO web site

XX
SQ Sequence 930 AA;

Query Match 100.0%; Score 51; DB 5; Length 930;
Best Local Similarity 100.0%; Pred. No. 13;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TYTFTDYVD 9
||||||||||
Db 369 TYTFTDYVD 377

RESULT 24
ADS06014
ID ADS06014 standard; protein; 930 AA.
XX
AC ADS06014;
XX
DT 04-NOV-2004 (first entry)
XX
DE Staphylococcus epidermis polypeptide seqid 5309.
XX
KW antibacterial; vaccine; antisense therapy; Staphylococcus epidermidis;
KW recombinant expression vector; infection; computer readable medium;
KW computer based system.
XX
OS Staphylococcus epidermidis.
XX
PN US2004147734-A1.
XX
PD 29-JUL-2004.
XX
PF 01-DEC-2003; 2003US-00724972.
XX
PR 08-NOV-1997; 97US-0064964P.
PR 13-AUG-1998; 98US-00134001.
PR 29-NOV-1999; 99US-00450969.
XX
PA (DOUC/) DOUCETTE-STAMM L.
PA (BUSH/) BUSH D.
XX
PI Doucette-Stamm L, Bush D;
XX
DR WPI; 2004-580138/56.
DR N-PSDB; ADS02242.
XX

PT New isolated polypeptide and encoding nucleic acid derived from
PT Staphylococcus epidermidis, useful for diagnosing, preventing and/or
PT treating an S. epidermidis bacterial infection.
XX
PS Claim 17; SEQ ID NO 5309; 741pp; English.
XX
CC The invention describes an isolated nucleic acid comprising a nucleotide
CC sequence with any of 3772 fully defined nucleotide sequences (SEQ ID NO:
CC 1-3772) and encoding an Staphylococcus epidermidis polypeptide with any
CC of 3772 fully defined amino acid sequences (SEQ ID NO: 3772-7544) as
CC given in the specification. Also described are: a recombinant expression
CC vector; a cell comprising a recombinant expression vector of (1);
CC producing an S. epidermidis polypeptide; an isolated nucleic acid
CC comprising a nucleotide sequence of at least 8 nucleotides in length; a
CC vaccine composition for prevention or treatment of an S. epidermidis
CC infection, comprising a nucleic acid cited above and a carrier; treating
CC a subject for S. epidermidis infection; a recombinant or substantially
CC pure preparation of an S. epidermidis polypeptide or its fragment; a
CC vaccine composition for prevention or treatment of an S. epidermidis
CC infection; detecting the presence of a Staphylococcus nucleic acid in a
CC sample; a computer readable medium having recorded in it the nucleotide
CC sequences with SEQ ID NO: 1-3772 or its fragments; a computer based
CC system for identifying fragments of the Staphylococcus genome of
CC commercial importance; a computer based system for identifying fragments
CC of the Staphylococcus plasmids of commercial importance; identifying
CC commercially important nucleic acid fragments of the Staphylococcus
CC genome and/or plasmids; and identifying an expression modulating fragment
CC of the Staphylococcus genome and/or plasmids. The methods and
CC compositions of the present invention are useful for the diagnosis,
CC prevention and/or treatment of an Staphylococcal epidermidis bacterial
CC infection. This is the amino acid sequence of a S. epidermis protein of
CC the invention.
XX
SQ Sequence 930 AA;

Query Match 100.0%; Score 51; DB 8; Length 930;
Best Local Similarity 100.0%; Pred. No. 13;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TYTFTDYVD 9
|||||||||
Db 369 TYTFTDYVD 377

ESULT 25
AEI12097
ID AEI12097 standard; protein; 930 AA.

XX
AC AEI12097;
XX
DT 10-AUG-2006 (first entry)
XX
DE Staphylococcus epidermidis protein amino acid sequence - SEQ ID 5309.
XX
KW staphylococcus infection; bacterial infection; antibacterial; vaccine;
KW diagnostic.
XX
OS Staphylococcus epidermidis.
XX
PN US7060458-B1.
XX
PD 13-JUN-2006.
XX
PF 29-NOV-1999; 99US-00450969.
XX
PR 14-AUG-1997; 97US-0055779P.
PR 08-NOV-1997; 97US-0064964P.
PR 13-AUG-1998; 98US-00134001.
XX
PA (AMHP) WYETH.
XX
PI Doucette-Stamm L, Bush D;
XX
DR WPI; 2006-413026/42.
DR N-PSDB; AEI08325.
XX
PT New nucleic acid encoding Staphylococcus epidermidis polypeptide, useful
PT for detecting, treating and preventing pathological conditions resulting
PT from bacterial infections.
XX
PS Disclosure; SEQ ID NO 5309; 588pp; English.
XX
CC The invention comprises the amino acid and coding sequences of
CC Staphylococcus epidermidis proteins, useful for detecting, treating, and
CC preventing (e.g. vaccine) bacterial infections. The present amino acid
CC sequence represents a Staphylococcus epidermidis protein of the
CC invention.
XX
SQ Sequence 930 AA;

Query Match 100.0%; Score 51; DB 10; Length 930;
Best Local Similarity 100.0%; Pred. No. 13;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TYTFTDYVD 9
||||||||
Db 369 TYTFTDYVD 377

RESULT 39
AAY08642
ID AAY08642 standard; protein; 1315 AA.
XX
AC AAY08642;
XX
DT 20-MAR-2003 (revised)
DT 09-AUG-1999 (first entry)
XX
DE S. aureus SdrD protein.
XX
KW Fibrinogen-binding protein; alpha chain; beta chain; ClfB; SdrC; SdrD;
KW SdrE; fibrinogen; medical device; competitive inhibitor; pharmaceutical;
KW treatment; infection; septicemia; osteomyelitis; mastitis; endocarditis;
KW extracellular matrix; vascular graft; vascular stent; vaccine;
KW intravenous catheter; artificial heart valve; cardiac assist device;
KW antibacterial.
XX
OS Staphylococcus aureus.
XX
PN WO9927109-A2.
XX
PD 03-JUN-1999.
XX
PF 25-NOV-1998; 98WO-US025246.
XX
PR 26-NOV-1997; 97US-0066815P.
PR 31-AUG-1998; 98US-0098427P.
XX
PA (INHI-) INHIBITEX INC.
PA (FORF-) FORFAS T/A BIORESEARCH IRELAND.
PA (TEXA) UNIV TEXAS A & M.
PA (PATT/) PATTI J M.
PA (FOST/) FOSTER T J.
PA (JOSE/) JOSEFSSON E.
PA (EIDH/) EIDHIN D N.
PA (HOOK/) HOOK M A O.
PA (PERK/) PERKINS S E.
XX
PI Patti JM, Foster TJ, Josefsson E, Eidhin DN, Hook MAO;
PI Perkins SE;

XX
DR WPI; 1999-357844/30.
DR N-PSDB; AAX77593.
XX
PT Staphylococcus aureus fibrinogen-binding proteins for treating
PT septicemia, osteomyelitis, mastitis or endocarditis.
XX
PS Claim 8; Fig 8; 143pp; English.
XX
CC This invention describes novel Staphylococcus aureus fibrinogen-binding
CC proteins that bind both the alpha and beta fibrinogen chains. The
CC proteins (and their encoding nucleic acids are ClfB, SdrC, SdrD and
CC SdrE). Staphylococcus aureus is thought to utilize fibrinogen to adhere
CC to medical devices, binding proteins that bind both the alpha and beta
CC fibrinogen chains (ClfB, SdrC, SdrD and SdrE) can therefore be used as
CC competitive inhibitors to block this binding. Antibodies against ClfB,
CC SdrC, SdrD and SdrE inhibit ClfB, SdrC, SdrD and SdrE mediated binding.
CC The proteins of the invention can be used in a pharmaceutical composition
CC for the treatment of Staphylococcus aureus infection e.g. septicemia,
CC osteomyelitis, mastitis or endocarditis or to inhibit the binding of S.
CC aureus to the extracellular matrix. The proteins or their fragments may
CC be used to coat a medical device to reduce the S. aureus infection of an
CC indwelling medical device, especially where the medical device is
CC selected from the group consisting of vascular grafts, vascular stents,
CC intravenous catheters, artificial heart valves, and cardiac assist
CC devices. ClfB, SdrC, SdrD, SdrE, or an active fragment, subdomain or
CC encoding gene may be used as a vaccine. The DS (aspartate serine) repeat
CC region or a gene encoding it may be used as an identifying probe for the
CC identification of genes and encoding proteins from Staphylococcus aureus
CC (other than CIfA), S. hemolyticus, S. lugdenensis, and S. schleriferi.
CC The proteins of the invention have antibacterial activity. (Updated on 20
CC -MAR-2003 to correct PA field.)
XX
SQ Sequence 1315 AA;

Query Match 100.0%; Score 51; DB 2; Length 1315;
Best Local Similarity 100.0%; Pred. No. 19;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TYTFTDYVD 9
||||||||| |
Db 339 TYTFTDYVD 347

RESULT 11
O70022_STAEP
ID O70022_STAEP PRELIMINARY; PRT; 1092 AA.

AC O70022;
DT 01-AUG-1998, integrated into UniProtKB/TrEMBL.
DT 01-AUG-1998, sequence version 1.
DT 13-JUN-2006, entry version 30.
DE Fibrinogen-binding protein precursor.
OS Staphylococcus epidermidis.
OC Bacteria; Firmicutes; Bacillales; Staphylococcus.
OX NCBI_TaxID=1282;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC STRAIN=HB;
RX MEDLINE=98261511; PubMed=9596732;
RA Nilsson M., Frykberg L., Flock J.I., Pei L., Lindberg M., Guss B.;
RT "A fibrinogen-binding protein of Staphylococcus epidermidis.";
RL Infect. Immun. 66:2666-2673(1998).
CC ----------

CC ----------
DR EMBL; Y17116; CAA76638.1; -; Genomic_DNA.
DR PIR; T30214; T30214.
DR HSSP; Q53653; 1N67.
DR SMR; O70022; 278-598.
DR GO; GO:0009986; C:cell surface; IEA.
DR GO; GO:0005618; C:cell wall; IEA.
DR GO; GO:0016020; C:membrane; IEA.
DR InterPro; IPR008966; Adhes_bact.
DR InterPro; IPR008454; Cna_B.
DR InterPro; IPR005877; Gpos_YSIRK.
DR InterPro; IPR001899; Gram_pos_anchor.
DR Pfam; PF05738; Cna_B; 2.
DR Pfam; PF00746; Gram_pos_anchor; 1.
DR Pfam; PF04650; YSIRK_signal; 1.
DR TIGRFAMs; TIGR01167; LPXTG_anchor; 1.
DR TIGRFAMs; TIGR01168; YSIRK_signal; 1.
DR PROSITE; PS50847; GRAM_POS_ANCHORING; 1.
KW Cell wall; Peptidoglycan-anchor; Signal.
FT SIGNAL 1 51 Potential.
FT CHAIN 52 1092 fibrinogen-binding protein.
SQ SEQUENCE 1092 AA; 119293 MW; 6542BC39AAD8B984 CRC64;

Query Match 100.0%; Score 51; DB 2; Length 1092;
Best Local Similarity 100.0%; Pred. No. 1.7;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TYTFTDYVD 9

Db 372 TYTFTDYVD 380

RESULT 4
US-09-147-405B-13
; Sequence 13, Application US/09147405B
; Patent No. 6733758
; GENERAL INFORMATION:
; APPLICANT: Guss, Bengt
; APPLICANT: Nilsson, Martin
; APPLICANT: Frykberg, Lars
; APPLICANT: Flock, Jan-Ingmar
; APPLICANT: Lindberg, Martin
; TITLE OF INVENTION: Fibrinogen Binding Protein Originating from
; TITLE OF INVENTION: Coagulase-Negative Staphylococcus
; FILE REFERENCE: guss 09/147405
; CURRENT APPLICATION NUMBER: US/09/147,405B
; CURRENT FILING DATE: 1999-04-11
; PRIOR APPLICATION NUMBER: PCT/SE97/10191
; PRIOR FILING DATE: 1997-06-18
; PRIOR APPLICATION NUMBER: SE 9602496-3
; PRIOR FILING DATE: 1996-06-20
; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 13
; LENGTH: 582
; TYPE: PRT
; ORGANISM: Staphylococcus epidermidis
US-09-147-405B-13

Query Match 100.0%; Score 51; DB 2; Length 582;
Best Local Similarity 100.0%; Pred. No. 1.7;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TYTFTDYVD 9
Db 298 TYTFTDYVD 306

RESULT 5
US-09-147-405B-11
; Sequence 11, Application US/09147405B
; Patent No. 6733758
; GENERAL INFORMATION:
; APPLICANT: Guss, Bengt
; APPLICANT: Nilsson, Martin
; APPLICANT: Frykberg, Lars

; APPLICANT: Flock, Jan-Ingmar
; APPLICANT: Lindberg, Martin
; TITLE OF INVENTION: Fibrinogen Binding Protein Originating from
; TITLE OF INVENTION: Coagulase-Negative Staphylococcus
; FILE REFERENCE: guss 09/147405
; CURRENT APPLICATION NUMBER: US/09/147,405B
; CURRENT FILING DATE: 1999-04-11
; PRIOR APPLICATION NUMBER: PCT/SE97/10191
; PRIOR FILING DATE: 1997-06-18
; PRIOR APPLICATION NUMBER: SE 9602496-3
; PRIOR FILING DATE: 1996-06-20
; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 11
; LENGTH: 593
; TYPE: PRT
; ORGANISM: Staphylococcus epidermidis
US-09-147-405B-11

Query Match 100.0%; Score 51; DB 2; Length 593;
Best Local Similarity 100.0%; Pred. No. 1.8;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TYTFTDYVD 9

Db 305 TYTFTDYVD 313

RESULT 6
US-09-134-001C-5314
; Sequence 5314, Application US/09134001C
; Patent No. 6380370
; GENERAL INFORMATION:
; APPLICANT: Lynn Doucette-Stamm et al
; TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO STAPHYLOCOCCUS
; TITLE OF INVENTION: EPIDERMIDIS FOR DIAGNOSTICS AND THERAPEUTICS
; FILE REFERENCE: GTC-007
; CURRENT APPLICATION NUMBER: US/09/134,001C
; CURRENT FILING DATE: 1998-08-13
; PRIOR APPLICATION NUMBER: US 60/064,964
; PRIOR FILING DATE: 1997-11-08
; PRIOR APPLICATION NUMBER: US 60/055,779
; PRIOR FILING DATE: 1997-08-14
; NUMBER OF SEQ ID NOS: 5674
; SEQ ID NO 5314

; LENGTH: 930
; TYPE: PRT
; ORGANISM: Staphylococcus epidermidis
US-09-134-001C-5314

Query Match 100.0%; Score 51; DB 2; Length 930;
Best Local Similarity 100.0%; Pred. No. 2.8;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TYTFTDYVD 9
||||||||
Db 369 TYTFTDYVD 377

RESULT 8
US-09-147-405B-15
; Sequence 15, Application US/09147405B
; Patent No. 6733758
; GENERAL INFORMATION:
; APPLICANT: Guss, Bengt
; APPLICANT: Nilsson, Martin
; APPLICANT: Frykberg, Lars
; APPLICANT: Flock, Jan-Ingmar
; APPLICANT: Lindberg, Martin
; TITLE OF INVENTION: Fibrinogen Binding Protein Originating from
; TITLE OF INVENTION: Coagulase-Negative Staphylococcus
; FILE REFERENCE: guss 09/147405
; CURRENT APPLICATION NUMBER: US/09/147,405B
; CURRENT FILING DATE: 1999-04-11
; PRIOR APPLICATION NUMBER: PCT/SE97/10191
; PRIOR FILING DATE: 1997-06-18
; PRIOR APPLICATION NUMBER: SE 9602496-3
; PRIOR FILING DATE: 1996-06-20
; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 15
; LENGTH: 1092
; TYPE: PRT
; ORGANISM: Staphylococcus epidermidis
US-09-147-405B-15

Query Match 100.0%; Score 51; DB 2; Length 1092;
Best Local Similarity 100.0%; Pred. No. 3.3;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TYTFTDYVD 9
||||||||

Db 372 TYTFTDYVD 380

RESULT 22
US-10-724-972A-5309
; Sequence 5309, Application US/10724972A
; Publication No. US20040147734A1
; GENERAL INFORMATION:
; APPLICANT: Doucette-Stamm, Lynn
; APPLICANT: Bush, David
; TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO STAPHYLOCOCCUS
; TITLE OF INVENTION: EPIDERMIDIS FOR DIAGNOSTICS AND THERAPEUTICS
; FILE REFERENCE: PATH03-16
; CURRENT APPLICATION NUMBER: US/10/724,972A
; CURRENT FILING DATE: 2003-12-01
; PRIOR APPLICATION NUMBER: 09/450,969
; PRIOR FILING DATE: 1999-11-29
; PRIOR APPLICATION NUMBER: 09/134,001
; PRIOR FILING DATE: 1998-08-13
; PRIOR APPLICATION NUMBER: 60/064,964
; PRIOR FILING DATE: 1997-11-08
; PRIOR APPLICATION NUMBER: 60/055,779
; PRIOR FILING DATE: 1997-08-14
; NUMBER OF SEQ ID NOS: 7544
; SEQ ID NO 5309
; LENGTH: 930
; TYPE: PRT
; ORGANISM: S.epidermidis
US-10-724-972A-5309

Query Match 100.0%; Score 51; DB 4; Length 930;
Best Local Similarity 100.0%; Pred. No. 9.7;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TYTFTDYVD 9
||||||||| |
Db 369 TYTFTDYVD 377
SEQ iD no. 10
RESULT 2
US-09-134-001C-5314
; Sequence 5314, Application US/09134001C
; Patent No. 6380370
; GENERAL INFORMATION:
; APPLICANT: Lynn Doucette-Stamm et al

; TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO STAPHYLOCOCCUS
; TITLE OF INVENTION: EPIDERMIDIS FOR DIAGNOSTICS AND THERAPEUTICS
; FILE REFERENCE: GTC-007
; CURRENT APPLICATION NUMBER: US/09/134,001C
; CURRENT FILING DATE: 1998-08-13
; PRIOR APPLICATION NUMBER: US 60/064,964
; PRIOR FILING DATE: 1997-11-08
; PRIOR APPLICATION NUMBER: US 60/055,779
; PRIOR FILING DATE: 1997-08-14
; NUMBER OF SEQ ID NOS: 5674
; SEQ ID NO 5314
; LENGTH: 930
; TYPE: PRT
; ORGANISM: Staphylococcus epidermidis
US-09-134-001C-5314

Query Match 99.9%; Score 4820; DB 2; Length 930;
Best Local Similarity 99.9%; Pred. No. 5.2e-256;
Matches 929; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1
LKKNNLLTKKKPIANKSNKYAIRKFTVGTASIVIGAALLFGLGHNEAKAEENTVQ
DVKDS 60
||||||||||||||||||||||||||||||||||| ||||||||||||||||||||
Db 1
LKKNNLLTKKKPIANKSNKYAIRKFTVGTASIVIGATLLFGLGHNEAKAEENTVQ
DVKDS 60

Qy 61
NMDDELSDSNDQSSNEEKNDVINNSQSINTDDDNQIKKEETNSNDAIENRSKDIT
QSTTN 120
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 61
NMDDELSDSNDQSSNEEKNDVINNSQSINTDDDNQIKKEETNSNDAIENRSKDIT
QSTTN 120

Qy 121
VDENEATFLQKTPQDNTQLKEEVVKEPSSVESSNSSMDTAQQPSHTTINSEASIQT
SDNE 180
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 121
VDENEATFLQKTPQDNTQLKEEVVKEPSSVESSNSSMDTAQQPSHTTINSEASIQT
SDNE 180

Qy 181
ENSRVSDFANSKIIESNTESNKEENTIEQPNKVREDSITSQPSSYKNIDEKISNQDEL
LN 240

Db 181
ENSRVSDFANSKIIESNTESNKEENTIEQPNKVREDSITSQPSSYKNIDEKISNQDEL
LN 240

Qy 241
LPINEYENKVRPLSTTSAQPSSKRVTVNQLAAEQGSNVNHLIKVTDQSITEGYDD
SDGII 300

Db 241
LPINEYENKVRPLSTTSAQPSSKRVTVNQLAAEQGSNVNHLIKVTDQSITEGYDD
SDGII 300

Qy 301
KAHDAENLIYDVTFEVDDKVKSGDTMTVNIDKNTVPSDLTDSFAIPKIKDNSGEII
ATGT 360

Db 301
KAHDAENLIYDVTFEVDDKVKSGDTMTVNIDKNTVPSDLTDSFAIPKIKDNSGEII
ATGT 360

Qy 361
YDNTNKQITYTFTDYVDKYENIKAHLKLTSYIDKSKVPNNNTKLDVEYKTALSS
VNKTIT 420

Db 361
YDNTNKQITYTFTDYVDKYENIKAHLKLTSYIDKSKVPNNNTKLDVEYKTALSS
VNKTIT 420

Qy 421
VEYQKPNENRTANLQSMFTNIDTKNHTVEQTIYINPLRYSAKETNVNISGNGDEG
STIID 480

Db 421
VEYQKPNENRTANLQSMFTNIDTKNHTVEQTIYINPLRYSAKETNVNISGNGDEG
STIID 480

Qy 481
DSTIIKVYKVGDNQNLPDSNRIYDYSEYEDVTNDDYAQLGNNNDVNINFGNIDSP
YIIKV 540

Db 481
DSTIIKVYKVGDNQNLPDSNRIYDYSEYEDVTNDDYAQLGNNNDVNINFGNIDSP
YIIKV 540

Qy 541
ISKYDPNKDDYTTIQQTVTMQTTINEYTGEFRTASYDNTIAFSTSSGQGQGDLPPE
KTYK 600

Db 541
ISKYDPNKDDYTTIQQTVTMQTTINEYTGEFRTASYDNTIAFSTSSGQGQGDLPPE
KTYK 600

Qy 601
IGDYVWEDVDKDGIQNTNDNEKPLSNVLVTLTYPDGTSKSVRTDEEGKYQFDGL
KNGLTY 660

Db 601
IGDYVWEDVDKDGIQNTNDNEKPLSNVLVTLTYPDGTSKSVRTDEEGKYQFDGL
KNGLTY 660

Qy 661
KITFETPEGYTPTLKHSGTNPALDSEGNSVWVTINGQDDMTIDSGFYQTPKYSLG
NYVWY 720

Db 661
KITFETPEGYTPTLKHSGTNPALDSEGNSVWVTINGQDDMTIDSGFYQTPKYSLG
NYVWY 720

Qy 721
DTNKDGIQGDDEKGISGVKVTLKDENGNIISTTTTDENGKYQFDNLNSGNYIVHF
DKPSG 780

Db 721
DTNKDGIQGDDEKGISGVKVTLKDENGNIISTTTTDENGKYQFDNLNSGNYIVHF
DKPSG 780

Qy 781
MTQTTTDSGDDDEQDADGEEVHVTITDHDDFSIDNGYYDDDSDSDSDSDSDSDD
SDSDSD 840

Db 781
MTQTTTDSGDDDEQDADGEEVHVTITDHDDFSIDNGYYDDDSDSDSDSDSDSDD
SDSDSD 840

Qy 841
SDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSGLDNSSDKNTKDKLPDTG
ANEDH 900
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 841
SDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSGLDNSSDKNTKDKLPDTG
ANEDH 900

Qy 901 DSKGTLLGALFAGLGALLLGKRRKNRKNKN 930
||||||||||||||||||||||||||||||
Db 901 DSKGTLLGALFAGLGALLLGKRRKNRKNKN 930

RESULT 3
US-11-208-208-5314
; Sequence 5314, Application US/11208208
; Publication No. US20070053936A1
; GENERAL INFORMATION:
; APPLICANT: Lynn Doucette-Stamm et al
; TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES
RELATING TO STAPHYLOCOCCUS
; TITLE OF INVENTION: EPIDERMIDIS FOR DIAGNOSTICS AND
THERAPEUTICS
; FILE REFERENCE: 032796-101
; CURRENT APPLICATION NUMBER: US/11/208,208
; CURRENT FILING DATE: 2005-08-22
; PRIOR APPLICATION NUMBER: US/10/902,441
; PRIOR FILING DATE: 2004-07-30
; PRIOR APPLICATION NUMBER: US 09/134,001
; PRIOR FILING DATE: 1998-08-13
; PRIOR APPLICATION NUMBER: US 60/064,964
; PRIOR FILING DATE: 1997-11-08
; PRIOR APPLICATION NUMBER: US 60/055,779
; PRIOR FILING DATE: 1997-08-14
; NUMBER OF SEQ ID NOS: 5676
; SEQ ID NO 5314
; LENGTH: 930
; TYPE: PRT
; ORGANISM: Staphylococcus epidermidis
US-11-208-208-5314

Query Match 99.9%; Score 4820; DB 7; Length 930;
Best Local Similarity 99.9%; Pred. No. 9.1e-200;
Matches 929; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1
LKKNNLLTKKKPIANKSNKYAIRKFTVGTASIVIGAALLFGLGHNEAKAEENTVQ
DVKDS 60

Db 1
LKKNNLLTKKKPIANKSNKYAIRKFTVGTASIVIGATLLFGLGHNEAKAEENTVQ
DVKDS 60

Qy 61
NMDDELSDSNDQSSNEEKNDVINNSQSINTDDDNQIKKEETNSNDAIENRSKDIT
QSTTN 120

Db 61
NMDDELSDSNDQSSNEEKNDVINNSQSINTDDDNQIKKEETNSNDAIENRSKDIT
QSTTN 120

Qy 121
VDENEATFLQKTPQDNTQLKEEVVKEPSSVESSNSSMDTAQQPSHTTINSEASIQT
SDNE 180

Db 121
VDENEATFLQKTPQDNTQLKEEVVKEPSSVESSNSSMDTAQQPSHTTINSEASIQT
SDNE 180

Qy 181
ENSRVSDFANSKIIESNTESNKEENTIEQPNKVREDSITSQPSSYKNIDEKISNQDEL
LN 240

Db 181
ENSRVSDFANSKIIESNTESNKEENTIEQPNKVREDSITSQPSSYKNIDEKISNQDEL
LN 240

Qy 241
LPINEYENKVRPLSTTSAQPSSKRVTVNQLAAEQGSNVNHLIKVTDQSITEGYDD
SDGII 300

Db 241
LPINEYENKVRPLSTTSAQPSSKRVTVNQLAAEQGSNVNHLIKVTDQSITEGYDD
SDGII 300

Qy 301
KAHDAENLIYDVTFEVDDKVKSGDTMTVNIDKNTVPSDLTDSFAIPKIKDNSGEII
ATGT 360

Db 301
KAHDAENLIYDVTFEVDDKVKSGDTMTVNIDKNTVPSDLTDSFAIPKIKDNSGEII
ATGT 360

Qy 361
YDNTNKQITYTFTDYVDKYENIKAHLKLTSYIDKSKVPNNNTKLDVEYKTALSS
VNKTIT 420

Db 361
YDNTNKQITYTFTDYVDKYENIKAHLKLTSYIDKSKVPNNNTKLDVEYKTALSS
VNKTIT 420

Qy 421
VEYQKPNENRTANLQSMFTNIDTKNHTVEQTIYINPLRYSAKETNVNISGNGDEG
STIID 480

Db 421
VEYQKPNENRTANLQSMFTNIDTKNHTVEQTIYINPLRYSAKETNVNISGNGDEG
STIID 480

Qy 481
DSTIIKVYKVGDNQNLPDSNRIYDYSEYEDVTNDDYAQLGNNNDVNINFGNIDSP
YIIKV 540

Db 481
DSTIIKVYKVGDNQNLPDSNRIYDYSEYEDVTNDDYAQLGNNNDVNINFGNIDSP
YIIKV 540

Qy 541
ISKYDPNKDDYTTIQQTVTMQTTINEYTGEFRTASYDNTIAFSTSSGQGQGDLPPE
KTYK 600

Db 541
ISKYDPNKDDYTTIQQTVTMQTTINEYTGEFRTASYDNTIAFSTSSGQGQGDLPPE
KTYK 600

Qy 601
IGDYVWEDVDKDGIQNTNDNEKPLSNVLVTLTYPDGTSKSVRTDEEGKYQFDGL
KNGLTY 660

Db 601
IGDYVWEDVDKDGIQNTNDNEKPLSNVLVTLTYPDGTSKSVRTDEEGKYQFDGL
KNGLTY 660

Qy 661
KITFETPEGYTPTLKHSGTNPALDSEGNSVWVTINGQDDMTIDSGFYQTPKYSLG
NYVWY 720

Db 661
KITFETPEGYTPTLKHSGTNPALDSEGNSVWVTINGQDDMTIDSGFYQTPKYSLG
NYVWY 720

Qy 721
DTNKDGIQGDDEKGISGVKVTLKDENGNIISTTTTDENGKYQFDNLNSGNYIVHF
DKPSG 780

Db 721
DTNKDGIQGDDEKGISGVKVTLKDENGNIISTTTTDENGKYQFDNLNSGNYIVHF
DKPSG 780

Qy 781
MTQTTTDSGDDDEQDADGEEVHVTITDHDDFSIDNGYYDDDSDSDSDSDSDSDD
SDSDSD 840

Db 781
MTQTTTDSGDDDEQDADGEEVHVTITDHDDFSIDNGYYDDDSDSDSDSDSDSDD
SDSDSD 840

Qy 841
SDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSGLDNSSDKNTKDKLPDTG
ANEDH 900

Db 841
SDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSDSGLDNSSDKNTKDKLPDTG
ANEDH 900

Qy 901 DSKGTLLGALFAGLGALLLGKRRKNRKNKN 930

Db 901 DSKGTLLGALFAGLGALLLGKRRKNRKNKN 930

RESULT 8
AAV04279
ID AAV04279 standard; DNA; 3600 BP.
XX
AC AAV04279;
XX
DT 17-OCT-2003 (revised)
DT 22-JUN-1998 (first entry)
XX

DE Staphylococcus epidermidis fibrinogen binding protein fig gene.
XX
KW Fibrinogen binding protein; fig gene; aggregation; infection;
KW coagulase-negative Staphylococcus; therapy; diagnosis; immunisation;
KW vaccine; ss.
XX
OS Staphylococcus epidermidis; strain HB.
XX
FH Key Location/Qualifiers
FT RBS 22. .27
FT /*tag= a
FT CDS 33. .3311
FT /*tag= b
FT sig_peptide 33. .185
FT /*tag= c
FT mat_peptide 186. .3308
FT /*tag= d
FT repeat_region 2502. .3151
FT /*tag= e
FT /note= "contains 18-bp sequence unit, repeated 36 times,
FT consensus GAXTCXGAXTCXGAXAGX, encoding Asp-Ser
FT dipeptides"
FT repeat_unit 2502. .2519
FT /*tag= f
FT /number= 1
FT repeat_unit 2520. .2531
FT /*tag= g
FT /number= 2
FT /note= "truncated repeat unit"
FT repeat_unit 2532. .2549
FT /*tag= h
FT /number= 3
FT repeat_unit 2550. .2567
FT /*tag= i
FT /number= 4
FT repeat_unit 2568. .2585
FT /*tag= j
FT /number= 5
FT repeat_unit 2586. .2603
FT /*tag= k
FT /number= 6
FT repeat_unit 2604. .2621
FT /*tag= l
FT /number= 7
FT repeat_unit 2622. .2639
FT /*tag= m

```
FT                   /number= 8
FT   repeat_unit     2640. .2657
FT                   /*tag= n
FT                   /number= 9
FT   repeat_unit     2658. .2675
FT                   /*tag= o
FT                   /number= 10
FT   repeat_unit     2676. .2693
FT                   /*tag= p
FT                   /number= 11
FT   repeat_unit     2694. .2711
FT                   /*tag= q
FT                   /number= 12
FT   repeat_unit     2712. .2729
FT                   /*tag= r
FT                   /number= 13
FT   repeat_unit     2730. .2747
FT                   /*tag= s
FT                   /number= 14
FT   repeat_unit     2748. .2765
FT                   /*tag= t
FT                   /number= 15
FT   repeat_unit     2766. .2783
FT                   /*tag= u
FT                   /number= 16
FT   repeat_unit     2784. .2801
FT                   /*tag= v
FT                   /number= 17
FT   repeat_unit     2802. .2819
FT                   /*tag= w
FT                   /number= 18
FT   repeat_unit     2820. .2837
FT                   /*tag= x
FT                   /number= 19
FT   repeat_unit     2838. .2855
FT                   /*tag= y
FT                   /number= 20
FT   repeat_unit     2856. .2873
FT                   /*tag= z
FT                   /number= 21
FT   repeat_unit     2874. .2891
FT                   /*tag= aa
FT                   /number= 22
FT   repeat_unit     2892. .2909
FT                   /*tag= ab
FT                   /number= 23
```

```
FT  repeat_unit    2910. .2927
FT                 /*tag= ac
FT                 /number= 24
FT  repeat_unit    2928. .2945
FT                 /*tag= ad
FT                 /number= 25
FT  repeat_unit    2944. .2961
FT                 /*tag= ae
FT                 /number= 26
FT  repeat_unit    2962. .2979
FT                 /*tag= af
FT                 /number= 27
FT  repeat_unit    2980. .2997
FT                 /*tag= ag
FT                 /number= 28
FT  repeat_unit    2998. .3015
FT                 /*tag= ah
FT                 /number= 29
FT  repeat_unit    3016. .3033
FT                 /*tag= ai
FT                 /number= 30
FT  repeat_unit    3034. .3051
FT                 /*tag= aj
FT                 /number= 31
FT  repeat_unit    3052. .3069
FT                 /*tag= ak
FT                 /number= 32
FT                 /note= "slight disruption of consensus"
FT  repeat_unit    3070. .3087
FT                 /*tag= al
FT                 /number= 33
FT  repeat_unit    3088. .3105
FT                 /*tag= am
FT                 /number= 34
FT                 /note= "slight disruption of consensus"
FT  repeat_unit    3106. .3123
FT                 /*tag= an
FT                 /number= 35
FT  repeat_unit    3124. .3151
FT                 /*tag= ao
FT                 /number= 36
FT                 /note= "slight disruption of consensus"
FT  repeat_unit    3457. .3463
FT                 /*tag= ap
FT                 /rpt_type= INVERTED
FT  repeat_unit    3471. .3477
```

FT /*tag= aq
FT /rpt_type= INVERTED
FT repeat_unit 3571..3578
FT /*tag= ar
FT /rpt_type= INVERTED
FT repeat_unit 3584..3591
FT /*tag= as
FT /rpt_type= INVERTED
XX
PN WO9748727-A1.
XX
PD 24-DEC-1997.
XX
PF 18-JUN-1997; 97WO-SE001091.
XX
PR 20-JUN-1996; 96SE-00002496.
XX
PA (GUSS/) GUSS B.
PA (NILS/) NILSSON M.
PA (FRYK/) FRYKBERG L.
PA (FLOC/) FLOCK J.
PA (LIND/) LINDBERG M.
XX
PI Guss B, Nilsson M, Frykberg L, Flock J, Lindberg M;
XX
DR WPI; 1998-063079/06.
DR P-PSDB; AAW41602.
XX
PT Fibrinogen-binding protein from coagulase-negative Staphylococcus - used
PT for prevention, treatment and diagnosis of Staphylococcus infection.
XX
PS Example 3; Fig 6; 45pp; English.
XX
CC The fig gene of coagulase-negative Staphylococcus epidermidis HB codes
CC for a 1092-amino acid fibrinogen binding protein (see AAW41602)
CC designated FIG. To isolate the gene, a phage library of HB was screened
CC for binding to fibrinogen-coated wells. Clone pSE100 was obtained that
CC encoded an incomplete FIG protein. The 3' and 5' ends were obtained by
CC screening chromosomal DNA using a probe generated by PCR (see AAV04280-
CC 81). The fig gene can be used in the recombinant production of FIG, and
CC also as a DNA vaccine to protect humans and animals against coagulase-
CC negative Staphylococcus infection. Probes based on the fig gene can be
CC used to identify S. epidermidis; fig is present in all strains of this
CC species but not in other staphyococci. Probes can also be used to
CC fingerprint strains (e.g. to identify a source of infection) and to
CC isolate similar genes from other species. (Updated on 17-OCT-2003 to

CC standardise OS field)
XX
SQ Sequence 3600 BP; 1418 A; 554 C; 665 G; 963 T; 0 U; 0 Other;

Query Match 81.9%; Score 2438.8; DB 2; Length 3600;
Best Local Similarity 94.8%; Pred. No. 0;
Matches 2559; Conservative 0; Mismatches 127; Indels 14; Gaps 3;

Qy 66 TACATTGAAATAGTCAAAGATAAGGAGTTTTTATGATTA--
AAAAAAAATAATTTACTAA 123
Db 1
TACATTGAAATAGTCAAAGAAAAGGAGTTTTTATGATTAATAAAAAAAATAA
TTTACTAA 60

Qy 124
CTAAAAAGAAACCTATAGCAAATAAATCCAATAAATATGCAATTAGAAAATT
CACAGTAG 183
Db 61
CTAAAAAGAAACCTATAGCAAATAAATCCAATAAATATGCAATTAGAAAATT
CACAGTAG 120

Qy 184
GTACAGCGTCTATTGTAATAGGTGCAGCATTATTGTTTGGTTTAGGTCATAAT
GAGGCCA 243
Db 121
GTACAGCGTCTATTGTAATAGGTGCAACATTATTGTTTGGTTTAGGTCATAAT
GAGGCCA 180

Qy 244
AAGCTGAGGAGAATACAGTACAAGACGTTAAAGATTCGAATATGGATGATG
AATTATCAG 303
Db 181
AAGCCGAGGAGAATTCAGTACAAGACGTTAAAGATTCGAATACGGATGATG
AATTATCAG 240

Qy 304
ATAGCAATGATCAGTCCAGTAATGAAGAAAAGAATGATGTAATCAATAATAG
TCAGTCAA 363
Db 241
ACAGCAATGATCAGTCTAGTGATGAAGAAAAGAATGATGTGATCAATAATAA
TCAGTCAA 300

Qy 364 TAAACACCGATGATGATAACCAAATA---
AAAAAAGAAGAAACGAATAGCAACGATGCCA 420

Db 301
TAAACACCGACGATAATAACCAAATAATTAAAAAAGAAGAAACGAATAACT
ACGATGGCA 360

Qy 421
TAGAAAATCGCTCTAAAGATATAACACAGTCAACAACAAATGTAGATGAAAA
CGAAGCAA 480

Db 361
TAGAAAAACGCTCAGAAGATAGAACAGAGTCAACAACAAATGTAGATGAAA
ACGAAGCAA 420

Qy 481
CATTTTTACAAAAGACCCCTCAAGATAATACTCAGCTTAAAGAAGAAGTGGT
AAAAGAAC 540

Db 421
CATTTTTACAAAAGACCCCTCAAGATAATACTCATCTTACAGAAGAAGAGGT
AAAAGAAT 480

Qy 541
CCTCATCAGTCGAATCCTCAAATTCATCAATGGATACTGCCCAACAACCATCT
CATACAA 600

Db 481
CCTCATCAGTCGAATCCTCAAATTCATCAATTGATACTGCCCAACAACCATCT
CACACAA 540

Qy 601
CAATAAATAGTGAAGCATCTATTCAAACAAGTGATAATGAAGAAAATTCCCG
CGTATCAG 660

Db 541
CAATAAATAGAGAAGAATCTGTTCAAACAAGTGATAATGTAGAAGATTCACA
CGTATCAG 600

Qy 661
ATTTTGCTAACTCTAAAATAATAGAGAGTAACACTGAATCCAATAAAGAAGA
GAATACTA 720

Db 601
ATTTTGCTAACTCTAAAATAAAAGAGAGTAACACTGAATCTGGTAAAGAAGA
GAATACTA 660

Qy 721
TAGAGCAACCTAACAAAGTAAGAGAAGATTCAATAACAAGTCAACCGTCTAG
CTATAAAA 780

Db 661
TAGAGCAACCTAATAAAGTAAAAGAAGATTCAACAACAAGTCAGCCGTCTGG
CTATACAA 720

Qy 781
ATATAGATGAAAAAATTTCAAATCAAGATGAGTTATTAAATTTACCAATAAA
TGAATATG 840

Db 721
ATATAGATGAAAAAATTTCAAATCAAGATGAGTTATTAAATTTACCAATAAA
TGAATATG 780

Qy 841
AAAATAAGGTTAGACCGTTATCTACAACATCTGCCCAACCATCGAGTAAGCG
TGTAACCG 900

Db 781
AAAATAAGGCTAGACCATTATCTACAACATCTGCCCAACCATCGATTAAACG
TGTAACCG 840

Qy 901
TAAATCAATTAGCGGCAGAACAAGGTTCGAATGTTAATCATTTAATTAAAGT
TACTGATC 960

Db 841
TAAATCAATTAGCGGCGGAACAAGGTTCGAATGTTAACCATTTAATTAAAGT
TACTGATC 900

Qy 961
AAAGTATTACTGAAGGATATGATGATAGTGATGGTATTATTAAAGCACATGA
TGCTGAAA 1020

Db 901
AAAGTATTACTGAAGGATATGATGATAGTGAAGGTGTTATTAAAGCACATGA
TGCTGAAA 960

Qy 1021
ACTTAATCTATGATGTAACTTTTGAAGTAGATGATAAGGTGAAATCTGGTGAT
ACGATGA 1080

Db 961
ACTTAATCTATGATGTAACTTTTGAAGTAGATGATAAGGTGAAATCTGGTGAT
ACGATGA 1020

Qy 1081
CAGTGAATATAGATAAGAATACAGTTCCATCAGATTTAACCGATAGTTTTGC
AATACCAA 1140

Db 1021
CAGTGGATATAGATAAGAATACAGTTCCATCAGATTTAACCGATAGCTTTAC
AATACCAA 1080

Qy 1141
AAATAAAAGATAATTCTGGAGAAATCATCGCTACAGGTACTTATGACAACAC
AAATAAAC 1200

Db 1081
AAATAAAAGATAATTCTGGAGAAATCATCGCTACAGGTACTTATGATAACAA
AAATAAAC 1140

Qy 1201
AAATTACCTACACTTTTACAGATTATGTAGATAAATATGAAAATATTAAAGC
GCACCTTA 1260

Db 1141
AAATCACCTATACTTTTACAGATTATGTAGATAAGTATGAAAATATTAAAGC
ACACCTTA 1200

Qy 1261
AATTAACATCATACATTGATAAATCAAAGGTTCCAAATAATAACACTAAGTT
AGATGTAG 1320

Db 1201
AATTAACGTCATACATTGATAAATCAAAGGTTCCAAATAATAATACCAAGTT
AGATGTAG 1260

Qy 1321
AATATAAGACGGCCCTTTCATCAGTAAATAAAACAATTACGGTTGAATATCA
AAAACCTA 1380

Db 1261
AATATAAAACGGCCCTTTCATCAGTAAATAAAACAATTACGGTTGAATATCA
AAGACCTA 1320

Qy 1381
ACGAAAATCGGACTGCTAACCTTCAAAGTATGTTCACAAACATAGATACGAA
AAACCATA 1440

Db 1321
ACGAAAATCGGACTGCTAACCTTCAAAGTATGTTTACAAATATAGATACGAA
AAATCATA 1380

Qy 1441
CAGTTGAGCAAACGATTTATATTAACCCTCTTCGTTATTCAGCCAAAGAAACA
AATGTAA 1500

Db 1381
CAGTTGAGCAAACGATTTATATTAACCCTCTTCGTTATTCAGCCAAGGAAACA
AATGTAA 1440

Qy 1501
ATATTTCAGGGAATGGCGATGAAGGTTCAACAATTATCGACGATAGTACAAT
CATTAAAG 1560

Db 1441
ATATTTCAGGGAATGGTGATGAAGGTTCAACAATTATAGACGATAGCACAAT
AATTAAAG 1500

Qy 1561
TTTATAAGGTTGGAGATAATCAAAATTTACCAGATAGTAACAGAATTTATGA
TTACAGTG 1620

Db 1501
TTTATAAGGTTGGAGATAATCAAAATTTACCAGATAGTAACAGAATTTATGA
TTACAGTG 1560

Qy 1621
AATATGAAGATGTCACAAATGATGATTATGCCCAATTAGGAAATAATAATGA
CGTGAATA 1680

Db 1561
AATATGAAGATGTCACAAATGATGATTATGCCCAATTAGGAAATAATAATGA
TGTGAATA 1620

Qy 1681
TTAATTTTGGTAATATAGATTCACCATATATTATTAAAGTTATTAGTAAATAT
GACCCTA 1740

Db 1621
TTAATTTTGGTAATATAGATTCACCATATATTATTAAAGTTATTAGTAAATAT
GACCCTA 1680

Qy 1741
ATAAGGACGATTACACGACGATACAGCAAACTGTGACAATGCAAACGACTAT
AAATGAGT 1800

Db 1681
ATAAGGATGATTACACGACTATACAGCAAACTGTGACAATGCAGACGACTAT
AAATGAGT 1740

Qy 1801
ATACTGGTGAGTTTAGAACAGCATCCTATGATAATACAATTGCTTTCTCTACA
AGTTCAG 1860

Db 1741
ATACTGGTGAGTTTAGAACAGCATCCTATGATAATACAATTGCTTTCTCTACA
AGTTCAG 1800

Qy 1861
GTCAAGGACAAGGTGACTTGCCTCCTGAAAAAACTTATAAAATCGGAGATTA
CGTATGGG 1920

Db 1801
GTCAAGGACAAGGTGACTTGCCTCCTGAAAAAACTTATAAAATCGGAGATTA
CGTATGGG 1860

Qy 1921
AAGATGTAGATAAAGATGGTATTCAAAATACAAATGATAATGAAAAACCGCT
TAGTAATG 1980

Db 1861
AAGATGTAGATAAAGATGGTATTCAAAATACAAATGATAATGAAAAACCGCT
TAGTAATG 1920

Qy 1981
TATTGGTAACTTTGACGTATCCTGATGGAACTTCAAAATCAGTCAGAACAGAT
GAAGAGG 2040

Db 1921
TATTGGTAACTTTGACGTATCCTGATGGAACTTCAAAATCAGTCAGAACAGAT
GAAGATG 1980

Qy 2041
GGAAATATCAATTTGATGGGTTAAAAAACGGATTGACTTATAAAATTACATT
CGAAACAC 2100

Db 1981
GGAAATATCAATTTGATGGATTGAAAAACGGATTGACTTATAAAATTACATT
CGAAACAC 2040

Qy 2101
CGGAAGGATATACGCCGACGCTTAAACATTCAGGAACAAATCCTGCACTAGA
CTCAGAAG 2160

Db 2041
CTGAAGGATATACGCCGACGCTTAAACATTCAGGAACAAATCCTGCACTAGA
CTCAGAAG 2100

Qy 2161
GCAATTCTGTATGGGTAACTATTAACGGACAAGACGATATGACTATTGATAG
CGGATTTT 2220

Db 2101
GTAATTCTGTATGGGTAACTATTAATGGACAAGACGATATGACGATTGATAG
TGGATTTT 2160

Qy 2221
ATCAAACACCTAAATATAGCTTAGGGAACTATGTATGGTATGACACTAATAA
AGATGGTA 2280

Db 2161
ATCAAACACCTAAATACAGCTTAGGGAACTATGTATGGTATGACACTAATAA
AGATGGTA 2220

Qy 2281
TTCAAGGTGATGATGAAAAAGGAATCTCTGGAGTAAAAGTGACGTTAAAAGA
TGAAAACG 2340

Db 2221
TTCAAGGTGATGATGAAAAAGGAATCTCTGGAGTTAAAGTGACGTTAAAAGA
TGAAAACG 2280

Qy 2341
GAAATATCATTAGTACAACAACAACTGATGAAAATGGAAAGTATCAATTTGA
TAATTTAA 2400

Db 2281
GAAATATCATTAGTACAACTACAACCGATGAAAATGGAAAGTATCAATTTGA
TAATTTAA 2340

Qy 2401
ATAGTGGTAATTATATTGTTCATTTTGATAAACCTTCAGGTATGACTCAAACA
ACAACAG 2460

Db 2341
ATAGTGGTAATTATATTGTTCATTTTGATAAACCTTCAGGTATGACTCAAACA
ACAACAG 2400

Qy 2461
ATTCTGGTGATGATGACGAACAGGATGCTGATGGGGAAGAAGTCCATGTAAC
AATTACTG 2520

Db 2401
ATTCTGGTGATGATGACGAACAGGATGCTGATGGGGAAGAAGTTCATGTAAC
AATTACTG 2460

Qy 2521
ATCATGATGACTTTAGTATAGATAACGGATACTATGATGACGACTCAGATTC
AGATAGTG 2580

Db 2461
ATCATGATGACTTTAGTATAGATAACGGATACTATGATGACGAATCGGATTC
CGATAGTG 2520

Qy 2581
ATTCAGACTCAGATAGCGACGACTCAGACTCCGATAGCGATTCCGACTCAGA
CAGCGACT 2640

Db 2521 ACTCAGA---------
CAGCGACTCAGATTCCGATAGTGATTCAGACTCCGATAGCGACT 2571

Qy 2641
CAGATTCCGATAGTGATTCAGATTCAGACAGTGACTCAGACTCAGATAGTGA
TTCAGATT 2700

Db 2572
CGGATTCAGACAGCGACTCAGATTCAGACAGCGACTCGGATTCTGATAGCGA
CTCGGATT 2631

Qy 2701
CAGACAGCGATTCCGACTCAGACAGTGACTCAGGATTAGACAATAGCTCAGA
TAAGAATA 2760

Db 2632
CAGACAGCGACTCAGACTCAGACAGTGATTCAGATTCAGACAGCGACTCAGA
TTCCGATA 2691